Canine Distemper Virus Neurologic Disease

Overview and Taxonomy of Canine Distemper Virus Neurologic Disease

Canine distemper virus (CDV), classified as Morbillivirus canis within the family Paramyxoviridae and genus Morbillivirus, represents one of the most significant multisystemic pathogens affecting terrestrial and aquatic carnivores globally [7, 11, 16]. As a member of the order Mononegavirales, CDV is an enveloped, single-stranded, negative-sense RNA virus that shares a close phylogenetic and pathogenic relationship with measles virus (MeV) in humans and the now-eradicated rinderpest virus of cattle [8, 18]. The World Organisation for Animal Health (WOAH) recognizes CDV as a notifiable pathogen due to its profound impact on animal health, conservation biology, and its potential role as a model for understanding morbillivirus pathogenesis in human medicine. The virus is responsible for a highly contagious, often fatal, systemic disease characterized by profound immunosuppression, severe respiratory and gastrointestinal involvement, and, most critically for the purposes of this treatise, a devastating array of acute and chronic neurologic manifestations that constitute the primary focus of this chapter.

Taxonomic Classification and Genomic Organization

Canine distemper virus is a prototypical morbillivirus, sharing the hallmark genomic organization of six structural proteins encoded in the order 3′-N-P-M-F-H-L-5′, with two non-structural proteins (C and V) expressed from the phosphoprotein (P) gene via RNA editing [13, 15]. The hemagglutinin (H) protein is the primary determinant of host tropism and antigenic diversity, serving as the receptor-binding protein that mediates viral attachment to host cellular receptors [8, 22, 24]. The fusion (F) protein facilitates membrane fusion and viral entry, while the nucleoprotein (N) encapsidates the viral RNA genome [15]. The large polymerase protein (L) and phosphoprotein (P) constitute the viral RNA-dependent RNA polymerase complex essential for replication and transcription.

Phylogenetic analysis of the H gene has become the gold standard for classifying CDV into distinct genetic lineages or genotypes, reflecting the virus's remarkable evolutionary capacity and geographic dissemination [16, 20]. To date, at least 17 major genotypes have been identified globally, including America-1 (the classical vaccinal lineage), America-2, America-3, America-4, South America/North America-4, Europe-1 (also designated Europe/South America-1), Europe-2 (European Wildlife), Europe-3 (Arctic-like), Asia-1, Asia-2, Asia-3, Asia-4, Asia-5, Africa-1, Africa-2, and the distinct Rockborn-like lineage [16, 20, 26]. This taxonomic framework is not merely a matter of academic classification; specific lineages exhibit differential geographic distribution, host predilection, and crucially, variable pathogenic potential for inducing neurologic disease [2, 27].

Global Distribution and Host Range

Canine distemper virus exhibits one of the broadest host ranges among all viral pathogens, infecting species across all families of the order Carnivora, including Canidae, Felidae, Mustelidae, Procyonidae, Ursidae, Viverridae, Hyaenidae, and Phocidae [7, 16, 18]. More alarmingly, CDV has demonstrated the capacity to cross species barriers into non-carnivore orders, including non-human primates such as macaques and marmosets, raising significant public health and conservation concerns [7, 23]. The virus is distributed across all continents except Antarctica, with endemic circulation in domestic dog populations serving as the primary reservoir for spillover events into wildlife [14, 19].

The taxonomic landscape is further complicated by the continuous emergence of novel lineages. Riley and Wilkes (2015) identified a genetically distinct lineage in the United States that appeared in 2011 and rapidly became the predominant strain detected in clinical submissions from multiple southeastern states [26]. This emerging lineage was associated with disease in both vaccinated adult dogs and wildlife, including foxes, and demonstrated significant antigenic differences from the vaccine strain, as evidenced by virus neutralization assays showing significantly lower neutralizing antibody titers against this novel strain [26]. Such findings underscore the critical importance of ongoing taxonomic surveillance to monitor for vaccine escape variants.

Neurologic Disease as a Taxonomic and Pathogenic Hallmark

The neurotropic potential of CDV distinguishes it from many other morbilliviruses and represents the most clinically devastating consequence of infection. Neurologic disease can manifest acutely during systemic infection or, uniquely, emerge weeks to months after apparent clinical recovery, a phenomenon termed "old dog encephalitis" in chronic cases [6, 12, 27]. The neuropathologic hallmark is demyelinating leukoencephalomyelitis, characterized by primary demyelination with relative axonal sparing, perivascular lymphohistiocytic cuffing, microglial nodules, and the presence of intranuclear and intracytoplasmic eosinophilic inclusion bodies within neurons, astrocytes, and oligodendrocytes [6, 25, 27].

The molecular taxonomy of CDV neurologic disease is intimately linked to specific mutations in the H protein, particularly at amino acid position 549. While domestic dog-adapted strains typically harbor a histidine (H) at this position, a tyrosine (Y) substitution at residue 549 (Y549H) has been strongly associated with enhanced virulence and expanded host range in wildlife species [10, 28]. Glišić and colleagues (2024) identified this Y549 mutation in CDV strains circulating in golden jackals from Serbia, suggesting adaptation to wildlife hosts [10]. Similarly, Trogu et al. (2022) documented the Y549H mutation in all CDV sequences obtained from foxes and badgers in northern Italy, linking this substitution with increased virulence and neurologic disease in these species [28].

Host Cellular Receptors and Neuroinvasion

The capacity of CDV to invade the central nervous system (CNS) and establish persistent infection is governed by viral receptor usage and host immune status. Wild-type CDV utilizes two canonical receptors: signaling lymphocyte activation molecule (SLAM/CD150) expressed on activated lymphocytes, macrophages, and dendritic cells, and nectin-4 (PVRL4), an adherens junction protein expressed on epithelial cells [5, 9, 23]. SLAM-dependent infection of immune cells facilitates systemic dissemination and profound immunosuppression, enabling viral entry into the CNS via infected lymphocytes trafficking across the blood-brain barrier, a mechanism termed the "Trojan horse" hypothesis [4, 23].

The recently identified low-density lipoprotein receptor-related protein 6 (LRP6) serves as a third entry receptor for attenuated vaccine strains, particularly the Onderstepoort strain, on cells lacking SLAM and nectin-4 expression [21]. This discovery has profound implications for understanding vaccine safety and the molecular basis of neurovirulence. Gradauskaite et al. (2023) demonstrated that LRP6 knockout renders cancer cells resistant to CDV-Onderstepoort infection, while ectopic expression restores susceptibility, establishing LRP6 as a functional entry factor for attenuated strains [21]. The differential expression of these receptors across neural cell types may explain the selective vulnerability of oligodendrocytes and the propensity for demyelination observed in CDV neurologic disease.

Genetic Diversity and Quasispecies Dynamics

RNA-dependent RNA polymerase lacks proofreading capability, resulting in high mutation rates and the generation of genetically diverse viral populations known as quasispecies [15]. This genetic diversity is a critical determinant of CDV's ability to adapt to new hosts, evade immune responses, and establish persistent neurologic infection. Siering and colleagues (2024) elegantly demonstrated that pre-existing genetic variability within a viral population facilitates rapid adaptation to ferrets, with mutations present at low frequency in the original inoculum serving as "genetic memory" that accelerates disease progression [15]. Importantly, the authors identified a conserved arginine residue at position 519 in the carboxy terminus of the nucleoprotein (N519R) that was shared across all adapted viruses and found to contribute to pathogenesis in ferrets [15]. This finding highlights how specific, single-nucleotide changes can profoundly influence neurovirulence.

The non-structural V protein, unique to paramyxoviruses, plays a pivotal role in CDV pathogenesis by antagonizing innate immune responses. Tian et al. (2024) demonstrated that the CDV V protein induces autophagy via inhibition of the PI3K/AKT/mTOR signaling pathway, a mechanism that promotes viral replication and may contribute to the persistence of viral RNA in neural tissues [13]. This autophagy induction may represent a double-edged sword: while initially antiviral, sustained autophagic flux could facilitate viral replication and contribute to the immunopathology observed in demyelinating lesions.

Implications for Global Health and Conservation

The taxonomic complexity and broad host range of CDV have profound implications for global health security and biodiversity conservation. The World Health Organization (WHO) and the WOAH recognize CDV as a pathogen of major concern in the context of the domestic animal-wildlife interface, where spillover events threaten endangered species [16, 19]. In Nepal, CDV strains belonging to the Asia-5 lineage have been documented in leopards exhibiting fatal neurologic disease, with phylogenetic evidence linking these strains to viruses circulating in local dog populations [1, 17]. Similarly, in the Russian Far East, Arctic-like lineage CDV strains caused fatal encephalitis in endangered Amur tigers, directly or indirectly killing approximately 1% of the remaining wild population in 2010 alone [3].

The Centers for Disease Control and Prevention (CDC) has highlighted the potential for morbilliviruses to emerge in novel hosts, a concern underscored by outbreaks of CDV in non-human primates and the documented ability of CDV to replicate in human cells expressing SLAM [8, 23]. The taxonomic classification of CDV strains, particularly through phylogenetic analysis of the H gene, provides essential information for vaccine design, outbreak investigation, and risk assessment for cross-species transmission events [20, 26]. The recognition that distinct genetic lineages may exhibit differential neurovirulence and antigenic properties underscores the necessity for continued molecular surveillance and lineage-level characterization of CDV strains associated with neurologic disease across diverse host species [2, 27].

Molecular Pathogenesis of Canine Distemper Virus Neurologic Disease

The molecular pathogenesis of neurologic disease caused by Canine Distemper Virus (CDV) represents a paradigm of viral neuroinvasion, immune evasion, and demyelination that has profound implications for both domestic and wild carnivore populations. As a member of the genus Morbillivirus within the family Paramyxoviridae, CDV is antigenically and structurally related to the human measles virus (MeV) and the now-eradicated rinderpest virus of cattle. The World Organisation for Animal Health (WOAH) recognizes CDV as a pathogen of significant economic and conservation concern, given its capacity to cause fatal encephalitis across a remarkably broad host range that spans terrestrial and aquatic mammals [1, 3, 8, 16]. Understanding the molecular events that underlie the transition from systemic infection to irreversible central nervous system (CNS) pathology is essential for the development of targeted therapeutics and for risk assessment in threatened species.

Viral Entry and Cellular Receptor Utilization as Determinants of Neurotropism

The initial molecular events governing CDV tropism are dictated by the viral hemagglutinin (H) protein, which mediates attachment to host cellular receptors. The canonical receptors for wild-type CDV are the signaling lymphocyte activation molecule (SLAM, also known as CD150) on cells of the immune system and nectin-4 (also known as poliovirus receptor-like 4 or PVRL4) on epithelial cells [4, 5, 21, 32]. SLAM is expressed on activated lymphocytes, macrophages, and dendritic cells, and its engagement by the CDV H protein constitutes the primary gateway for systemic dissemination following initial respiratory tract infection. Upon inhalation, CDV first encounters alveolar macrophages and dendritic cells within the respiratory epithelium. These sentinel cells become infected, and the virus is subsequently trafficked to local lymphoid tissues, where massive replication in SLAM-expressing lymphocytes and monocytes precipitates the profound and characteristic immunosuppression that defines the acute phase of disease [4, 5, 32, 33]. This early lymphotropism is not merely a passive transport mechanism but an active strategy that disarms the host's adaptive immune response before significant neuronal invasion occurs. Studies using fluorescent reporter-expressing recombinant CDV (rCDV) in ferrets and raccoons have demonstrated that lymphoid tissues, including the tonsils, mandibular lymph nodes, spleen, and Peyer's patches, are sites of explosive viral replication within days of inoculation, with infected lymphocytes and myeloid cells serving as vehicles for hematogenous and lymphatic dissemination to distant organs, including the CNS [5, 23].

The transition from lymphoid tropism to epithelial and neuronal tropism is mediated by the interaction of the CDV H protein with nectin-4, a cell adhesion molecule located at adherens junctions in epithelial cells. This receptor is critical for viral shedding and horizontal transmission, as it facilitates infection of respiratory, gastrointestinal, and urothelial epithelia [4, 5]. However, the molecular mechanisms by which CDV penetrates the blood-brain barrier (BBB) to gain access to the CNS remain an area of active investigation. It is hypothesized that infected mononuclear cells, specifically, CDV-infected lymphocytes and monocytes, traverse the BBB via diapedesis, effectively acting as a "Trojan horse" that introduces the virus into the perivascular space. Once within the CNS parenchyma, the virus must then adapt to infect resident neural cells, which do not express SLAM or nectin-4 at appreciable levels under normal physiological conditions. This adaptation is thought to require mutations in the H protein that facilitate entry through alternative receptors, potentially including the low-density lipoprotein receptor-related protein 6 (LRP6), which has been identified as a functional receptor for the attenuated Onderstepoort (OP) strain of CDV in cells lacking SLAM and nectin-4 [21]. The discovery that LRP6, a member of the Wnt signaling pathway, can serve as an entry factor raises the intriguing possibility that similar receptors may be upregulated on glial cells or neurons during inflammation, thereby facilitating or enhancing viral spread within the CNS. This molecular plasticity of the H protein is a critical determinant of CDV's remarkable ability to cross species barriers and adapt to new hosts, as evidenced by the identification of specific mutations (e.g., Y549H) in wildlife-adapted strains that are associated with enhanced virulence and altered receptor binding properties [10, 28].

Immunopathogenesis and Subversion of Host Antiviral Defenses

CDV's success as a neuropathogen is inextricably linked to its capacity to subvert the host immune response at multiple levels. The virus encodes two non-structural proteins, V and C, which are expressed from the phosphoprotein (P) gene and act as potent antagonists of the host interferon (IFN) system [4, 13]. The V protein, in particular, blocks IFN signaling by interfering with the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, thereby inhibiting the establishment of an antiviral state in infected and bystander cells. Furthermore, the V protein has been shown to induce autophagy via inhibition of the PI3K/AKT/mTOR signaling pathway, a cellular process that normally promotes cell survival under stress but is co-opted by CDV to enhance viral replication [13]. This autophagy induction is not a passive byproduct of infection but a direct, molecularly defined mechanism: the CDV V protein physically interacts with PI3K, leading to the suppression of downstream AKT and mTOR phosphorylation, which in turn triggers autophagosome formation and facilitates viral RNA synthesis and virion production [13]. This finding has profound implications for neurologic disease, as aberrant autophagy in neurons and glia can contribute to demyelination and neurodegeneration.

The profound lymphopenia and immunosuppression observed in acute CDV infection result from the direct infection and subsequent depletion of CD4+ T lymphocytes, B lymphocytes, and myeloid cells [4, 5, 23]. In experimentally infected ferrets and raccoons, high infection percentages in immune cells lead to a rapid and dramatic depletion of these cells from both circulation and lymphoid tissues, often in the absence of a detectable neutralizing antibody response [5, 23]. This state of immunological paralysis allows the virus to replicate unchecked, reaching high titers in systemic tissues and facilitating early invasion of the CNS. The virus also targets dendritic cells (DCs), impairing their ability to process and present antigen, thereby crippling the initiation of adaptive immunity [4]. Transcriptomic analyses of CDV-infected alveolar macrophages have revealed that attenuated vaccine strains (e.g., Onderstepoort) induce a robust type I IFN-related pro-inflammatory response, whereas virulent field strains (e.g., R252) suppress these pathways, showing much weaker expression of IFN-stimulated genes [32]. This differential induction of innate immunity is a key molecular correlate of attenuation: vaccine strains trigger a potent antiviral state that restricts viral spread, whereas wild-type strains effectively silence this response, allowing for unrestricted dissemination to the CNS [32, 36].

Mechanisms of Demyelination and Neuropathology

The hallmark neuropathological lesion of CDV neurologic disease is demyelinating leukoencephalitis, a condition characterized by primary demyelination with relative sparing of axons, perivascular lymphohistiocytic cuffing, gliosis, and the presence of intranuclear and intracytoplasmic eosinophilic inclusion bodies (Lentz corpuscles) [3, 6, 27, 29]. These lesions are most frequently observed in the cerebellum, brainstem, and cervical spinal cord, correlating with the clinical presentation of ataxia, myoclonus, and vestibular dysfunction [12, 30, 35]. The molecular pathogenesis of demyelination is multifactorial, involving both direct viral cytopathology and immune-mediated injury. In the acute phase, CDV infects oligodendrocytes, the myelin-producing cells of the CNS, leading to their death and subsequent demyelination. However, in chronic and older lesions, the virus may become restricted to astrocytes and microglia, and the ongoing demyelination is driven by a persistent, non-productive infection that triggers a delayed-type hypersensitivity reaction. Infected astrocytes upregulate MHC class II molecules, potentially presenting viral antigens to infiltrating CD4+ T lymphocytes, which in turn release pro-inflammatory cytokines (e.g., TNF-α, IFN-γ) that damage neighboring oligodendrocytes and myelin sheaths [4, 27]. This immune-mediated mechanism is supported by the observation that CDV-induced demyelination in dogs shares striking histopathological and immunopathological similarities with multiple sclerosis (MS) in humans, making CDV a valuable spontaneous animal model for this human demyelinating disease [4, 12].

The non-structural protein V also plays a role in facilitating viral replication within the CNS by inducing autophagy, as previously detailed. This process may contribute to the persistence of viral RNA and antigen in neural tissues long after the resolution of acute systemic infection, a phenomenon known as "old dog encephalitis" or chronic progressive encephalomyelitis. In these chronic forms, the virus can be detected by PCR and immunohistochemistry in the brains of animals that have recovered from systemic disease, sometimes months or years later, suggesting that the CNS serves as a sanctuary site for viral persistence [29, 34]. The molecular basis for this persistence involves the downregulation of viral gene expression, such that the virus evades immune surveillance while continuing to cause low-level tissue damage. This persistent infection is particularly challenging for diagnosis, as routine antigen detection tests on mucosal swabs or blood frequently yield false-negative results, necessitating the analysis of cerebrospinal fluid (CSF) by RT-PCR or the detection of intrathecal anti-CDV antibodies for ante-mortem confirmation [2, 37].

Molecular Factors Governing Species Barrier Crossing and Virulence

The molecular evolution of the CDV H protein is a primary driver of the virus's expanding host range and the emergence of neurologic disease in novel species. Comparative phylogenetic analyses of the H gene have identified at least 17 distinct genetic lineages globally, including America-1 (vaccine lineage), Europe/South America-1, Arctic-like, Asia-1, Asia-5, and European Wildlife lineages [8, 16, 20]. The emergence of specific mutations in the H protein, particularly at amino acid position 549, is strongly associated with adaptation to non-canid hosts. The presence of a tyrosine (Y) at residue 549, as opposed to the histidine (H) commonly found in domestic dog strains, has been identified in viruses isolated from wild carnivores such as golden jackals, foxes, and raccoons [10, 28]. This Y549H mutation is believed to alter the conformation of the receptor-binding site, potentially enhancing the virus's affinity for SLAM orthologs in distantly related species or facilitating entry via alternative receptors [10, 20]. Such molecular adaptations are not merely phylogenetic curiosities but are functionally linked to the ability of CDV to cause fatal epidemics in endangered species, including Amur tigers, leopards, and Eurasian lynx [1, 3, 6, 17].

The Arctic-like lineage, which has been responsible for devastating outbreaks in Baikal seals and Amur tigers, demonstrates that even host-switching events between marine and terrestrial mammals are possible, driven by molecular changes in the H protein that permit infection of pinniped SLAM [3, 20]. Similarly, the Asia-5 lineage has been implicated in fatal neurologic disease in leopards in Nepal and is closely related to strains circulating in domestic dogs in the same region, underscoring the threat posed by free-roaming dog populations at the wildlife-domestic interface [1, 17, 31]. The high genetic diversity of CDV as an RNA virus, with error-prone RNA-dependent RNA polymerase generating a diverse quasispecies swarm, provides the raw material for rapid adaptation to new hosts and the immune pressures exerted by vaccination. Studies using deep sequencing have demonstrated that pre-existing minor genetic variants within the quasispecies can serve as "genetic memory," allowing for rapid selection of advantageous mutations during host-switching events [15]. This phenomenon has practical implications for vaccine efficacy: strains belonging to the America-1 lineage (vaccine strains) may not fully protect against antigenically divergent wild-type strains from other lineages, such as the emerging CDV strains in the United States that have been detected in fully vaccinated dogs [26]. Therefore, the molecular surveillance of circulating H gene sequences is essential for updating vaccine formulations and predicting the risk of neurologic disease outbreaks in both domestic and wild populations.

Epidemiology of Canine Distemper Neurologic Disease: Host Range, Transmission, and Risk Factors

Canine distemper virus (CDV), a highly contagious morbillivirus within the family Paramyxoviridae, represents one of the most significant multi-host pathogens affecting terrestrial and aquatic mammals worldwide. The neurologic sequelae of CDV infection, characterized by demyelinating leukoencephalitis, nonsuppurative meningoencephalomyelitis, and chronic progressive encephalitis, are among the most devastating manifestations of this disease, carrying a grave prognosis and often resulting in mortality or necessitating euthanasia. Understanding the intricate epidemiology of neurologic CDV disease requires a comprehensive examination of its remarkably broad host range, complex transmission dynamics, and the constellation of risk factors that predispose individuals and populations to central nervous system (CNS) involvement. This section synthesizes data from over six decades of investigation, incorporating molecular phylogenetics, experimental pathogenesis studies, and large-scale passive and active surveillance to provide an authoritative account of the epidemiologic landscape of CDV neurologic disease.

Host Range: From Domestic Dogs to Endangered Apex Predators

The host range of CDV extends across virtually all families of the order Carnivora and, notably, into non-human primates, underscoring its status as a generalist pathogen with extraordinary cross-species capability [4, 8, 16]. A comprehensive scoping review and spatial meta-analysis of 160 published studies encompassing 457 individual records from 1985 to 2024 revealed that CDV has been detected in hosts belonging to Canidae (75.2% of records), Mustelidae (9.7%), Procyonidae (7.6%), and Felidae (5.1%) [16]. Within the Canidae, the domestic dog (Canis lupus familiaris) remains the most frequently reported host (40% of records), while the red fox (Vulpes vulpes) is the predominant wild host (30.2%) [16]. However, the capacity of CDV to induce neurologic disease has been documented in a startling diversity of species, including endangered apex predators such as the Amur tiger (Panthera tigris altaica), the Bengal tiger (P. tigris tigris), the Indian leopard (P. pardus fusca), the Javan leopard (P. pardus melas), and the Eurasian lynx (Lynx lynx) [1, 3, 6, 17, 29, 46].

Felids were historically considered resistant to CDV, but a seminal 1983 report of chronic encephalomyelitis in a Bengal tiger provided early neuropathologic evidence of susceptibility, with nonsuppurative meningoencephalomyelitis, demyelination, and inclusion bodies typical of CDV [29]. Subsequent investigations in the Russian Far East definitively established CDV as the etiology of fatal neurologic disease in wild Amur tigers, with immunohistochemical and molecular confirmation of infection in animals presenting with severe encephalitis [3]. The 2010 cluster of cases alone accounted for approximately 1% of the remaining wild Amur tiger population, highlighting the profound conservation threat posed by this virus [3]. Phylogenetic analysis of tiger-derived CDV sequences grouped them within an Arctic-like strain lineage also found in Baikal seals, suggesting a potential marine reservoir or, more plausibly, a shared terrestrial source [3]. In Nepal, fatal neurologic disease in leopards has been linked to the Asia-5 lineage, with seroprevalence reaching 30% (6/20) among sampled leopards, compared to 11% (3/28) in Bengal tigers; notably, more than one-third of seropositive felids were symptomatic, and three died within a week of sampling [17]. Dietary analyses indicate that leopards in Nepal frequently predate upon domestic dogs, providing a plausible route of CDV acquisition, whereas tigers rarely do, which may explain the lower seroprevalence in tigers [17].

Beyond large felids, CDV neurologic disease has been reported in a diverse array of mesocarnivores and mustelids. In the United States, surveillance data from the Southeastern Cooperative Wildlife Disease Study (1975–2019) documented 964 CDV-positive cases across 17 states, predominantly in raccoons (Procyon lotor; 67%), gray foxes (Urocyon cinereoargenteus; 26%), and striped skunks (Mephitis mephitis; 3.4%) [41]. Importantly, neurologic signs consistent with CDV encephalitis were a common reason for submission. In the Czech Republic, a survey of 412 wild animals from 2012–2020 found an overall CDV prevalence of 18%, with the highest positivity in red foxes (28%), raccoons (43%), and pine martens (20%); statistical differences in positivity among species were highly significant (p < 0.0001) [44]. The virus has also been detected in golden jackals (Canis aureus) in Serbia, with all sequenced H genes clustering within the Arctic lineage and harboring a tyrosine (Y) at position 549, a mutation commonly associated with wildlife adaptation rather than the histidine (H) typically found in domestic dog strains [10]. This Y549H substitution has been linked to enhanced virulence in wildlife, as demonstrated in a study of CDV-infected foxes and badgers in northern Italy, where the Y549H mutation was present in all sequences collected, coinciding with increased mortality [28].

The capacity of CDV to cause neurologic disease in non-human primates was confirmed by a lethal outbreak in free-ranging black-tufted marmosets (Callithrix penicillata) in Brazil, where affected animals presented with neurologic signs and were found to have pantropic viral distribution, including in the CNS [7]. Viral sequences were closely related to South American lineages and Vero cell-adapted strains, raising concerns about spillover from domestic dogs into neotropical primate populations [7]. Even species not traditionally considered highly susceptible, such as the white-nosed coati (Nasua narica) in Ecuador and the Marsican brown bear (Ursus arctos marsicanus) in Italy, have been found to harbor CDV, with the bear strain identical to those circulating in sympatric foxes and dogs, indicating a shared viral lineage at the domestic–wild interface [47, 48].

The molecular basis for this expansive host range lies in the virus’s use of two well-characterized cellular receptors: signaling lymphocyte activation molecule (SLAM/CD150) on immune cells and nectin-4 on epithelial cells [4, 32]. However, recent discovery of low-density lipoprotein receptor-related protein 6 (LRP6) as a functional entry receptor for the attenuated Onderstepoort strain in cells lacking SLAM and nectin-4 suggests additional, yet unidentified, receptors may facilitate infection in diverse hosts [21]. Variability in the SLAM receptor amino acid sequence among species has been proposed to influence species-specific disease manifestation. A comparative study of SLAM in coyotes, raccoons, and skunks revealed 36 nucleotide differences among 263 aligned base pairs, with 8 of 11 predicted amino acid residues differing between coyotes (canid) and raccoons/skunks (non-canids); electrostatic potential surface alterations at the viral interface were noted, potentially impacting receptor binding and subsequent disease severity [9]. This may explain why CDV is diagnosed more frequently and with greater severity in raccoons and skunks than in coyotes within the same geographic region [9].

Transmission Dynamics: Reservoirs, Spillover, and Spatial-Temporal Patterns

Transmission of CDV occurs primarily via aerosolized respiratory secretions, direct contact with infected body fluids, and fomites [4, 8]. The virus is shed in respiratory secretions, feces, urine, and skin exudates, with the highest viral loads detected during the acute phase of infection [2, 34]. Following respiratory entry, CDV replicates initially in alveolar macrophages and regional lymphoid tissues, leading to a cell-associated viremia that disseminates to multiple organ systems, including the CNS [5, 23, 32]. In experimentally inoculated raccoons, rCDV-infected white blood cells were detected as early as 4 days post-inoculation (dpi), with lymphoid replication preceding spread to peripheral tissues by 21 dpi; CNS invasion was observed at later time points, and infected animals remained severely immunosuppressed with prolonged shedding, supporting the role of raccoons as important maintenance hosts [23].

The domestic dog is widely regarded as the primary reservoir for CDV, particularly in regions with high free-roaming dog populations and low vaccination coverage [14, 19]. A systematic review of CDV in African wildlife (1978–2021) identified 65 relevant articles; among 23 reports that investigated the role of domestic dogs as reservoirs, 61% concluded that dogs acted as sources of infection for wildlife [14]. In Nepal’s Chitwan National Park, seroprevalence of CDV in free-roaming dogs reached 80% (95% CI: 70.8–87.3), with adult dogs having significantly higher odds of seropositivity (OR = 9.00) compared to juveniles, suggesting widespread environmental exposure [19]. Phylogenetic analysis of CDV strains from stray dogs in Kathmandu Valley revealed the Asia-5 lineage, identical to strains found in Indian lions, civets, and red pandas, indicating a sylvatic cycle maintained among sympatric carnivores that allows recurring spillover events [31]. Similarly, in the United States, a distinct CDV lineage that first appeared in 2011 and was detected in dogs from multiple southeastern states was also found in wildlife submissions, suggesting a stable wildlife reservoir that may facilitate vaccine escape [26].

Transmission at the domestic–wild interface is bidirectional and facilitated by ecological overlap, anthropogenic habitat fragmentation, and the movement of reservoir hosts. The presence of free-roaming dogs around protected areas represents a significant source of infectious CDV for endangered wildlife [19]. In the Russian Far East, the geographic distribution of CDV-positive Amur tigers across an expansive area suggests wide dissemination of the virus, likely maintained by sympatric canids [3]. In the Aosta Valley of Italy, CDV prevalence in red foxes (60%), wolves (14%), badgers (47%), and beech martens (51%) was found to correlate with landscape fragmentation, as measured by NDVI entropy from satellite remote sensing; areas with higher habitat heterogeneity and human–wildlife interface showed increased CDV transmission [42]. This finding underscores the utility of geospatial tools in predicting disease spread and informing One Health management policies [42].

Temporal patterns in CDV epizootiology reveal distinct seasonality in certain regions. In a retrospective study of dogs with neurologic CDV in southern Brazil, the highest occurrence of neurologic signs was recorded during autumn [30]. In Illinois, CDV infection in skunks peaked during winter–spring, coinciding with periods of increased social contact and breeding [39]. Analysis of raccoon and gray fox cases in Georgia (USA) using autoregressive integrated moving average models demonstrated that cases were more likely to occur during breeding seasons, and spatial clustering was most pronounced in areas of medium to high human population density, likely reflecting high raccoon densities in suburban environments [41]. Interestingly, fewer cases occurred in both the most densely populated and most sparsely populated areas, indicating a nonlinear relationship between human population density and CDV transmission risk [41].

Risk Factors for Neurologic Disease

The progression from systemic CDV infection to neurologic involvement is governed by a complex interplay of host, viral, and environmental factors. Age is a well-established risk factor. In a study of 70 CDV-suspected unvaccinated dogs in Iran, dogs older than 12 months exhibited the highest percentage of distemper contamination in the neurologic group, whereas dogs aged 3–6 months were more affected in the non-neurologic group [2]. This paradoxical age distribution may reflect the transient protection of maternal antibodies in younger puppies, which wanes by 6–12 months, leaving older juveniles and young adults susceptible to severe disease, including neurologic complications. Conversely, a large retrospective analysis in Brazil (2025) involving dogs with confirmed CNS disorders identified younger dogs as having a significantly increased likelihood of developing neurologic CDV (p = 0.00690; log odds ratio [LOR] = −0.01438), suggesting that age effects may be population- and strain-dependent [30].

Breed predisposition has been identified in certain canine populations. Shih Tzu (p = 0.00007; LOR = 1.53774) and Lhasa Apso (p = 0.000264; LOR = 1.76084) breeds showed a significantly increased likelihood of neurologic CDV compared to other breeds in the Brazilian study [30]. The authors hypothesized that breed-specific genetic factors, possibly related to immune response genes or CNS vulnerability, may contribute to this increased risk. Sex and neuter status did not emerge as significant predictors in multivariable analysis, although univariable associations with male dogs showing lower seroprevalence than females have been reported in free-roaming dog populations [19].

Vaccination status is a critical but often confounding risk factor. While vaccination with modified-live CDV vaccines is highly effective in preventing systemic disease and CNS involvement, breakthrough infections can occur. In the Brazilian study, many CDV-infected dogs with neurologic signs had an updated vaccination protocol, suggesting either vaccine failure due to antigenic mismatch between circulating strains and vaccine strains, or waning immunity [30]. Indeed, a new CDV lineage that emerged in the United States in 2011 was detected in fully vaccinated adult dogs and showed significant differences in neutralizing antibody titers against the vaccine strain, indicating potential vaccine escape [26]. Post-vaccinal CDV encephalitis, albeit rare, has been documented in puppies receiving live attenuated vaccines. A case series of nine puppies in New Zealand (8–13 weeks old) developed neurologic signs 9–23 days after vaccination; whole genome sequencing confirmed a Rockborn-like strain with 99.9% homology to the vaccine virus, and histopathology revealed lymphohistiocytic encephalitis or meningoencephalitis [25]. Similar post-vaccinal distemper has been reported in two litters in Finland, where vaccine strain RNA was identified in CNS lesions [45], and in a 14-week-old puppy in Canada with PCR-positive brain tissue matching the Rockborn strain [43]. These cases highlight the potential for reversion to virulence or host-mediated vaccine-strain dissemination in immunologically immature or compromised individuals.

Genetic diversity of the virus itself constitutes a major risk factor for neurologic disease. CDV, as an RNA virus, exists as a quasispecies with high mutation rates, enabling rapid adaptation to new hosts and tissues [15]. Experimental adaptation of CDV to ferrets demonstrated that pre-existing mutations in the viral population facilitated faster adaptation to the new host, with a common arginine at position 519 of the nucleoprotein associated with increased pathogenesis [15]. The hemagglutinin (H) protein, responsible for receptor binding and host range determination, exhibits substantial genetic variability among lineages. A study of 286 H gene sequences from 25 countries (1930–2020) identified 11 globally co-circulating lineages, with the America-1 lineage (vaccine origin) being the most widely distributed but not necessarily the most virulent [20]. The widespread occurrence of neurologic CDV in wildlife is often associated with specific mutations, such as the Y549H substitution in the H protein that enhances binding to canine SLAM and correlates with increased virulence in non-canid hosts [10, 28]. Furthermore, viral tropism for the CNS is influenced by the ability to infect microglial cells, astrocytes, and oligodendrocytes, leading to demyelination. The non-structural protein V of CDV induces autophagy via the PI3K/AKT/mTOR pathway to facilitate viral replication, and this mechanism may be particularly active in neural cells, contributing to the development of neurologic lesions [13].

Environmental and ecological risk factors also play a role. Seasonality, as noted, influences transmission rates, with autumn and winter peaks in many regions [30, 39]. Coinfections with other pathogens can exacerbate neurologic disease. In gray foxes, concurrent infection with skunk adenovirus-1 and Listeria monocytogenes was identified alongside CDV, with the CDV strain belonging to a regionally specific clade unique to New England wildlife [38]. Similarly, in the Czech Republic, coinfections with Toxoplasma gondii and CDV have been documented, though the impact on neurologic outcome remains unclear [40]. In marmosets, coinfection with Callitrichinae gammaherpesvirus 3 was detected in three animals [7]. The severe immunosuppression induced by CDV, resulting from massive infection and depletion of CD4+ Th1 lymphocytes and disruption of interferon and cytokine signaling, predisposes hosts to secondary infections that may accelerate neurologic decline [4].

Finally, host genetics at the population level influence susceptibility to neurologic CDV. The differential expression and structural variation of SLAM among species, as discussed above, modulate the efficiency of viral entry and dissemination [9]. In addition, the recent discovery of LRP6 as an alternative entry receptor for attenuated CDV strains raises the possibility that novel receptors may exist for wild-type strains in different hosts, potentially explaining the seemingly unpredictable patterns of neurologic disease in non-canid species [21]. The sheer breadth of susceptible hosts, from domestic dogs to endangered tigers, from raccoons to marmosets, necessitates a comprehensive One Health approach to CDV surveillance and control, integrating vaccination of domestic reservoirs, habitat management, and real-time molecular monitoring of circulating strains. The World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) have recognized CDV as a pathogen of conservation significance, and ongoing efforts by the US Centers for Disease Control and Prevention (CDC) and other global health agencies emphasize the importance of cross-species disease surveillance in mitigating the impact of this formidable virus.

Clinical Manifestations and Neuropathology of Canine Distemper Virus Infection

Initial Systemic Phase and Progression to Neurologic Involvement

The clinical trajectory of canine distemper virus (CDV) infection is notoriously variable, yet a cardinal feature remains the frequent progression from a multisystemic, often respiratory and gastrointestinal, syndrome to a devastating and frequently fatal neurologic disease. The initial systemic phase, typically appearing 1–4 weeks post-exposure, is characterized by pyrexia, serous to mucopurulent oculonasal discharges, conjunctivitis, anorexia, and lethargy [2, 51, 54]. Gastrointestinal signs, including vomiting and diarrhea, are common, occurring in approximately 38.63% of cases in some clinical surveys, while cutaneous manifestations such as hyperkeratosis of the footpads and nasal planum (“hard pad disease”) are noted in over half of infected dogs [54]. The emergence of neurologic signs can occur concurrently with systemic illness, may follow an apparent recovery from the acute phase, or can manifest weeks to months later as a chronic, progressive encephalomyelitis [6, 27, 29]. This temporal unpredictability underscores the viral neurotropism and the complex interplay between viral persistence and host immune responses.

The prevalence of neurologic involvement in CDV is exceptionally high. In a detailed clinical characterization of 44 confirmed CDV-positive dogs, nervous system signs were observed in an astounding 97.72% of cases, highlighting that neurologic disease represents a near-ubiquitous endpoint in clinically apparent infections [54]. This aligns with retrospective studies indicating that mortality and lethality rates for CDV-induced neurologic disease can reach 47.06%, with a median survival time of 754 days, but with the caveat that many animals are euthanized due to the severity of their condition [30]. The high prevalence of neurologic signs is a direct reflection of the virus’s ability to invade the central nervous system (CNS) via infected lymphocytes (the “Trojan horse” mechanism) or via direct infection of endothelial cells and choroid plexus epithelium, breaching the blood-brain barrier [4, 23].

Spectrum of Neurologic Syndromes: From Myoclonus to Encephalitis

The clinical signs of CDV-induced neurologic disease are protean, reflecting the widespread distribution of viral lesions throughout the neuraxis. Neurologic deficits are overwhelmingly multifocal, as documented in epidemiological studies where most infected dogs exhibited involvement of multiple CNS regions [30]. Among the most characteristic and pathognomonic signs is myoclonus, involuntary, rhythmic, and repetitive contractions of a muscle or group of muscles. This is frequently reported in the literature, often manifesting as “chewing gum fits” (rhythmic jaw movements) or persistent twitching of limb or facial muscles [29, 35, 52]. Myoclonus is notorious for its persistence; it may remain as a permanent sequela even in animals that otherwise recover from the acute infection.

Seizures are another prominent and distressing manifestation, ranging from focal motor seizures to generalized tonic-clonic convulsions [25, 29, 35, 50]. Status epilepticus may occur and carries a grave prognosis. Cerebellar and vestibular signs are also common, presenting as ataxia, dysmetria, head tilt, nystagmus, and intention tremors [6, 29]. Spinal cord involvement can lead to paresis or paralysis, often progressing from paraparesis to tetraparesis [6, 29]. Behavioral changes, including disorientation, aggression, and loss of learned behaviors, are frequently reported in wildlife and domestic cases alike, and are a hallmark of cortical involvement [6, 38]. The variability in clinical expression is further complicated by the observation that dogs with acute, rapidly progressive encephalitis may die within days, while others experience a chronic, smoldering course over months [27, 35]. Interestingly, visual evoked potentials (VEPs) have recently been investigated as a potential subclinical marker of CNS damage. In a study of dogs naturally infected with CDV, significantly prolonged latencies of VEP waves (N1, P1, N2, P2, N3) were detected in the absence of alterations in the electroretinogram or wave amplitudes. This suggests that demyelinating lesions within the optic radiations or visual cortex may be detectable via electrophysiological testing even before overt clinical signs of visual impairment emerge [12].

Influence of Age, Breed, and Viral Lineage on Neurologic Phenotype

Epidemiological risk factor analyses have identified age and breed as critical determinants of susceptibility to CDV neurologic disease. A large retrospective study from Brazil revealed that younger dogs have a significantly increased likelihood of developing neurologic signs following CDV infection (p = 0.00690; log odds ratio [LOR] = -0.01438), indicating an inverse relationship between age and risk [30]. This is likely a reflection of the immature immune system’s inability to contain viral replication and prevent CNS invasion. Conversely, in the context of non-neurologic CDV, the highest incidence was observed in dogs aged 3–6 months, whereas in neurologic CDV cases, dogs older than 12 months were most affected, suggesting that late-onset or chronic neurologic disease may be more common in older animals that survive the initial systemic phase [2].

Breed predisposition is also significant. In the same Brazilian study, Shih Tzu (p = 0.00007; LOR = 1.53774) and Lhasa Apso (p = 0.000264; LOR = 1.76084) breeds demonstrated a markedly increased likelihood of developing CDV-associated neurologic signs compared to mixed-breed dogs [30]. The biological basis for this breed susceptibility remains unknown but may involve genetic polymorphisms in immune response genes or in the signaling lymphocyte activation molecule (SLAM/CD150) receptor, which is essential for viral entry into lymphoid cells. Partial SLAM gene sequencing in free-ranging coyotes, raccoons, and skunks has revealed species-specific amino acid differences at the predicted viral interface, with 8 of 11 variable residues differing between canids and non-canids [9]. These differences correlated with altered electrostatic potential on the receptor surface, suggesting that subtle changes in receptor structure can influence virulence and disease outcome across species boundaries. While such data are not yet available for dog breeds, it is a plausible area for future investigation.

Viral genotype also plays a role in neurovirulence. Phylogenetic studies have shown that distinct CDV lineages, such as the Arctic-like lineage in Iran, the Asia-5 lineage in Nepal, and the EU1/SA1 lineage in South America, can all cause neurologic disease, but the specific clinical presentation and severity may vary [1, 2, 27]. In golden jackals (Canis aureus) from Serbia, a mutation at position 549 of the H protein (tyrosine instead of histidine) was identified, which has been previously associated with a broader host range and potentially increased neurovirulence, underscoring the virus’s adaptability and the role of the H protein in receptor binding and cell tropism [10].

Neuropathology: Demyelination, Inclusion Bodies, and Inflammatory Responses

The neuropathologic hallmarks of CDV infection are pathognomonic and include demyelinating leukoencephalitis, multifocal perivascular lymphohistiocytic cuffing, gliosis, and the presence of eosinophilic intranuclear and intracytoplasmic inclusion bodies (Lentz corpuscles) within neurons, astrocytes, and oligodendrocytes [3, 6, 27, 29]. Demyelination is the most characteristic lesion and is particularly prominent in the cerebellum, brainstem, and spinal cord. It is a biphasic process: an early, non-inflammatory phase caused by direct viral cytopathic effect on oligodendrocytes, followed by a later, secondary inflammatory phase mediated by immune responses, including activated microglia and infiltrating T cells, that exacerbates myelin destruction [6, 12]. The demyelination is often multifocal and confluent, and in chronic cases, can lead to severe cavitation and glial scarring [6].

Inflammatory lesions are non-suppurative in nature, with perivascular aggregates of lymphocytes, plasma cells, and macrophages forming cuffs that are one to several cell layers thick [39, 49]. Meningoencephalitis and meningomyelitis are common, with lymphohistiocytic infiltration of the leptomeninges and choroid plexus [6, 27]. Glial nodules, focal aggregates of reactive astrocytes and microglial cells, are frequently observed, particularly in gray matter structures such as the cerebral cortex, thalamus, and basal ganglia [39, 43, 49]. Inclusion bodies are a critical diagnostic feature; they are eosinophilic and can be found in the nucleus or cytoplasm of infected cells. They are most consistently identified in the cerebellum (Purkinje cells, granular layer neurons), brainstem, and spinal cord, but can also be seen in ependymal cells and choroid plexus epithelium [3, 27].

Immunohistochemistry (IHC) for CDV antigen has become a gold standard for confirming diagnosis in histologic sections. Positive immunolabeling is typically observed in the cytoplasm and processes of astrocytes and neurons, as well as in axons, perivascular lymphocytes, and ependymal cells [27]. The distribution of viral antigen closely mirrors the distribution of lesions, with high concentrations in the white matter of the cerebellum and brainstem, regions most severely affected by demyelination [3, 27]. In situ hybridization (ISH) techniques have further confirmed the presence of viral RNA in these regions, providing molecular confirmation of the histopathologic findings [3].

Comparative Neuropathology Across Species

The neuropathology of CDV is remarkably conserved across a wide range of mammalian hosts, although subtle variations exist. In endangered Amur tigers (Panthera tigris altaica) from the Russian Far East, necropsy of two fatal cases revealed non-suppurative encephalitis with severe demyelination and eosinophilic intranuclear viral inclusions in brain tissue. IHC and ISH demonstrated positive labeling for CDV antigen and RNA, respectively, confirming the virus as the causative agent of neurologic disease [3]. Similarly, in a Eurasian lynx (Lynx lynx) from Austria, histologic examination revealed multifocal demyelinating lesions in the cerebellum, brainstem, and cervical spinal cord, accompanied by multifocal, perivascular lymphohistiocytic meningoencephalitis. IHC and RT-PCR confirmed a chronic CDV infection, indistinguishable from the classic chronic distemper encephalitis seen in dogs [6].

In a Bengal tiger (Panthera tigris tigris) that exhibited chronic progressive neurologic signs over 18 months, neuropathologic findings included non-suppurative meningoencephalomyelitis, perivascular cuffing, demyelination, and inclusion bodies typical of CDV. Interestingly, this case was notable for the marked increase in neutralizing antibodies in both serum and cerebrospinal fluid, indicative of a persistent, immunologically driven encephalitis [29]. The high seroprevalence observed in free-ranging leopards (Panthera pardus) and tigers in Nepal (30% and 11%, respectively) underscores the frequent exposure of these species to CDV, with a substantial proportion of seropositive animals exhibiting clinical neurologic signs and dying within days of sampling [17].

In the context of neotropical primates, a lethal CDV outbreak in free-ranging black-tufted marmosets (Callithrix penicillata) in Brazil demonstrated that this virus can cause severe neurologic disease, cutaneous lesions, and death in non-human primates. Histopathologic examination showed a pantropic distribution of viral antigen by IHC, with involvement of the CNS, consistent with the severe encephalitis observed [7]. These cases collectively illustrate that CDV is a pantropic pathogen with a conserved neuropathogenic signature that transcends taxonomic boundaries, making it a significant conservation threat for a vast array of wild carnivores and even non-human primates.

The Immune Pathogenesis of Neuropathology

The development of neurologic disease in CDV infection is intricately linked to the host’s immune status. The virus initially targets lymphoid tissues, macrophages, dendritic cells, and lymphocytes, via the SLAM/CD150 receptor, leading to profound and lasting immunosuppression [4, 5, 32]. This immunosuppression is characterized by lymphopenia, depletion of B and T cells from lymphoid follicles, and a skewing of the immune response toward a Th1-dominated, pro-inflammatory state that paradoxically may contribute to tissue damage [4, 36]. The ability of the virus to block interferon signaling pathways and induce autophagy via the PI3K/AKT/mTOR pathway (mediated by the non-structural V protein) further facilitates viral replication and evasion of the immune response [13].

In the CNS, the virus infects microglia, astrocytes, and neurons. The early non-inflammatory demyelination is thought to result from direct viral cytolysis of oligodendrocytes, while the later inflammatory demyelination is mediated by an exaggerated immune response, including the infiltration of CD8+ cytotoxic T cells and activated macrophages, which release pro-inflammatory cytokines that damage myelin sheaths [4, 12, 36]. Transcriptomic analyses of CDV-infected canine lungs have shown a robust type I interferon response and upregulation of genes associated with innate immunity and cell death, suggesting that a similar process occurs in the CNS during the acute phase, but that the virus eventually subverts these responses to establish persistence [36]. The chronic, progressive nature of some neurologic forms of CDV is thought to be due to a failure of the immune system to clear the virus from the CNS, leading to ongoing inflammation and demyelination [4, 29].

Post-Vaccinal and Vaccine-Associated Neurologic Disease

A rare but critical complication of live attenuated CDV vaccination is the development of post-vaccinal distemper, which can manifest as a severe neurologic syndrome. In a series of nine cases in New Zealand, puppies aged 8–13 weeks developed seizures, circling, tremors, hypersalivation, and progressive neurologic deficits 9–23 days after receiving a quadrivalent vaccine containing a live attenuated CDV (Rockborn-like strain). Histopathologic findings were typical of distemper encephalitis, including mononuclear/lymphohistiocytic meningoencephalitis with neuronal intranuclear inclusion bodies. Immunohistochemistry was positive for CDV in neural tissues, and whole genome sequencing confirmed the vaccine strain in affected tissues [25]. Similar cases have been documented in Finland, where two litters of puppies developed severe disease, one with lymphoid necrosis and another with encephalitis, after vaccination. In both litters, the vaccine strain was confirmed via IHC and RNA sequencing, raising the possibility of an underlying immunodeficiency in the affected animals [45]. A further case in Canada described a 14-week-old puppy with pyrexia, pruritic rash, and focal seizures that progressed to death. Despite the absence of classic histologic signs like demyelination or inclusion bodies, PCR and IHC of brain tissue were positive for the Rockborn vaccine strain, highlighting the fact that neuropathologic presentation can be atypical in vaccine-induced disease [43].

These cases underscore that while live attenuated CDV vaccines are generally safe, reversion to virulence or inadequate attenuation can, on rare occasions, produce neurologic disease indistinguishable from natural infection. This is particularly relevant for conservation medicine, where vaccination of endangered species with live vaccines carries a risk of inducing disease, as observed in African wild dogs (Lycaon pictus) where one pup died of suspected CDV neurologic disease within 17 days of vaccination [53].

Conclusion of Section

The clinical manifestations and neuropathology of CDV infection represent a devastating continuum from systemic illness to chronic, progressive encephalomyelitis. The virus’s ability to infect and persist within the CNS, coupled with its capacity to induce intense inflammatory and demyelinating responses, results in a broad spectrum of neurologic signs including myoclonus, seizures, ataxia, and paresis. The neuropathologic signature is consistent across a vast array of species, from domestic dogs to endangered tigers and primates, featuring demyelination, perivascular cuffing, and intranuclear inclusion bodies. Age, breed, and viral genotype influence the clinical phenotype, while recent reports of post-vaccinal distemper highlight the potential risks associated with live attenuated vaccines. As CDV continues to emerge as a significant threat to wildlife conservation, a deep understanding of its neuropathogenesis is essential for developing effective diagnostic, therapeutic, and prophylactic strategies.

Diagnostic Approaches for Canine Distemper Neurologic Disease: Molecular, Serological, and Cerebrospinal Fluid Analysis

The accurate and timely diagnosis of canine distemper virus (CDV) neurologic disease presents a formidable challenge in veterinary medicine, compounded by the virus's pantropic nature, the variable temporal onset of neurological signs relative to systemic infection, and the clinical overlap with other encephalitides such as rabies, toxoplasmosis, neosporosis, and non-infectious inflammatory conditions. A definitive antemortem diagnosis of neurologic distemper cannot be rendered through clinical observation alone, as the spectrum of central nervous system (CNS) manifestations, ranging from subtle behavioral changes and myoclonus to fulminant seizures and progressive ataxia, is non-pathognomonic [2, 30, 35]. Consequently, a multi-modal diagnostic framework integrating molecular detection, serological interrogation, and cerebrospinal fluid (CSF) analysis is essential. The World Organisation for Animal Health (WOAH) recognizes CDV as a significant multi-host pathogen of global importance, and the diagnostic strategies employed must account for viral strain diversity, the immunological status of the host, and the specific compartment (systemic versus neural) being sampled.

Molecular Diagnostics: Amplification and Genotyping

Reverse transcription polymerase chain reaction (RT-PCR) and its quantitative variants (RT-qPCR, droplet digital PCR) constitute the gold standard for the direct detection of CDV nucleic acid, offering superior sensitivity and specificity compared to antigen-based assays, particularly in the context of neurologic disease [8, 58]. The choice of target gene is critical; the hemagglutinin (H) gene is most frequently employed for phylogenetic analyses and lineage determination due to its high genetic variability, while the nucleoprotein (N) and phosphoprotein (P) genes are conserved targets well-suited for diagnostic screening [11, 16, 44].

Sample Selection and Sensitivity in Neurologic Cases: The selection of biological material profoundly influences diagnostic yield. In dogs presenting with acute systemic signs, conjunctival swabs, nasal exudate, and whole blood are adequate, with a high concordance to RT-PCR [2, 54]. However, in cases of chronic, purely neurologic distemper where systemic viral shedding has ceased, the sensitivity of peripheral samples diminishes dramatically. Mojtahedzadeh et al. [2] demonstrated that in neurologic CDV cases with negative rapid antigen tests, RT-PCR of CSF exhibited the highest sensitivity, serving as a critical diagnostic arbiter. Sarchahi et al. [37] corroborated this, reporting that CSF RT-PCR was positive in 80% of dogs with neurologic signs, compared to only 55% positivity in whole blood. This phenomenon is attributed to the viral sequestration within the CNS parenchyma following clearance from peripheral lymphoid and epithelial tissues [34, 37]. The detection of viral RNA in CSF is therefore a potent indicator of active CNS infection, even when systemic markers have waned.

Quantitative and Digital PCR: While conventional RT-PCR is highly sensitive, RT-qPCR provides quantification of viral load, which can inform prognosis and monitor the course of infection. Brown et al. [55] validated a portable, point-of-care (POC) qPCR platform (Biomeme two3™) for field use in wildlife, demonstrating comparable sensitivity to laboratory-based methods for detecting CDV in suspect cases. Although a decrease in sensitivity (average 5.1 cycles higher Ct values) was noted with animal samples, the technology is invaluable for rapid onsite diagnosis in remote settings, enabling differentiation from rabies and facilitating conservation interventions [55, 56]. More recently, droplet digital PCR (ddPCR) has emerged as a superior technology for detecting low-abundance targets. Iribarnegaray et al. [58] reported that ddPCR achieved a detection limit of 3 copies/μL, versus 86 copies/μL for RT-qPCR, with a clinical sensitivity of 72.4% compared to 57.9% for RT-qPCR. The superior sensitivity of ddPCR is particularly relevant for detecting residual viral RNA in CSF or brain tissue from animals with chronic demyelinating encephalitis, where viral replication is low-grade and compartmentalized [58].

Genotyping and Strain Characterization: Molecular diagnostics extend beyond mere detection. Sequencing of the H gene is indispensable for characterizing circulating strains and understanding epizootiological linkages between domestic and wild carnivores. The identification of specific lineages, such as Arctic-like, Asia-1, Europe/South America-1, and the America-2 subclades, has profound implications for vaccine efficacy and cross-species transmission risk [2, 20, 26, 60]. For instance, the emergence of a distinct genetic lineage in the United States in 2011 was associated with disease in vaccinated dogs, suggesting potential vaccine escape [26]. Similarly, the identification of the Asia-5 lineage in leopards in Nepal [1] and the Arctic-like lineage in Amur tigers in Russia [3] underscores the need for lineage-specific surveillance. Molecular diagnostics also enable the detection of virulence-associated mutations, such as the Y549H substitution in the H protein, which has been linked to increased pathogenicity in wildlife [28]. The use of multiplex panels allows simultaneous screening for CDV alongside other respiratory or enteric pathogens, streamlining the diagnostic process in complex clinical presentations [11, 59].

Serological Analysis: Interpreting the Humoral Response

Serological assays detect host antibodies against CDV, providing evidence of past or current exposure. However, their interpretation in the context of neurologic disease requires careful nuance, as the presence of systemic antibodies does not always correlate with CNS infection.

Serum Neutralizing Antibodies: Virus neutralization tests (VNT) remain the reference standard for quantifying protective immunity. Seroprevalence studies in wildlife, such as those in tigers and leopards in Nepal [17] and free-roaming dogs surrounding Chitwan National Park [19], have revealed exposure rates ranging from 11% to 80%, highlighting the endemic nature of the virus. In vaccinated populations, the presence of high neutralizing antibody titers is generally protective, yet vaccine failures are increasingly documented due to genetic mismatch between vaccine strains (primarily America-1/ Ondesterpoort lineage) and contemporary field strains [27]. Feijóo et al. [27] described four vaccinated dogs that succumbed to neurologic CDV, with post-mortem characterization identifying South American wild-type strains (EU1/SA1) not present in the vaccine. This underscores the limitation of serology as a sole diagnostic tool for neurologic disease; a high antibody titer may reflect prior vaccination or exposure rather than active CNS infection.

Intrathecal Antibody Production: A more specific serological approach for neurologic distemper is the detection of intrathecal antibody synthesis. In chronic, progressive encephalitis, measles virus in humans and CDV in dogs can drive a sustained, compartmentalized humoral immune response within the CNS. Blythe et al. [29] documented marked increases in neutralizing antibodies against CDV in both serum and CSF of a Bengal tiger with chronic encephalomyelitis. The demonstration of a higher antibody titer in CSF relative to serum, or the presence of oligoclonal immunoglobulin bands, can serve as indirect evidence of active CNS infection. This is particularly valuable in cases where PCR is negative due to low viral replication or prior antiviral therapy.

Antigen Detection Limitations: Rapid immunochromatographic (IC) antigen test kits, while convenient for field use, demonstrate poor sensitivity in neurologic cases. Curti et al. [51] found that IC tests were positive in all dogs with systemic signs but uniformly negative in dogs presenting exclusively with neurologic signs. Mohan et al. [54] reported a mere 31.82% sensitivity for the rapid antigen test compared to PCR. This failure is attributable to the low concentration of viral antigen in peripheral secretions during the neurologic phase [51, 54]. Consequently, a negative IC test in a neurologically affected animal does not rule out CDV, and molecular testing of CSF is mandatory [2, 37].

Cerebrospinal Fluid Analysis: A Window into the CNS

CSF analysis is arguably the most informative antemortem diagnostic modality for CDV neurologic disease. It provides a unique opportunity to directly sample the CNS milieu for both viral components and indices of neuroinflammation.

Cytology and Biochemistry: The typical CSF profile in CDV encephalitis is that of a lymphocytic or mixed mononuclear pleocytosis, with mild to moderate protein elevation. In the study by Sarchahi et al. [35], CSF was collected from dogs with neurologic signs and analyzed; the presence of mononuclear cells is consistent with the characteristic histopathological finding of non-suppurative meningoencephalomyelitis [3, 6, 29]. However, these changes are not pathognomonic, as similar profiles are observed in other viral encephalitides (e.g., rabies) and immune-mediated conditions. Therefore, cytology alone is insufficient for a definitive diagnosis but provides supportive evidence of CNS inflammation.

Virus Detection in CSF: As discussed, RT-PCR on CSF is the most sensitive method for confirming neurologic distemper [2, 37]. The study by Sarchahi et al. [37] is particularly instructive, showing that in dogs with neurologic signs only (without concurrent systemic manifestations), CSF RT-PCR was positive in 16/20 dogs, while mucosal IC tests and blood PCR were positive in only 10/20 and 11/20, respectively. This aligns with the pathogenesis of CDV, which can persist in the CNS for weeks to months after peripheral viral clearance [34]. The detection of viral RNA in CSF, even at low levels via ddPCR [58], is therefore diagnostic.

CSF Antibodies and Immune Complexes: In chronic cases, where viral RNA may be undetectable, measurement of CDV-specific IgG and IgM in CSF can be diagnostic. The antibody index (AI), calculated as the ratio of CDV-specific antibody in CSF to that in serum, corrected for total IgG and albumin, can differentiate intrathecal synthesis from passive antibody transfer due to blood-brain barrier disruption. An elevated AI is strongly indicative of active CNS infection and has been used successfully in cases of chronic distemper encephalitis [29].

Histopathology and Immunohistochemistry: While technically post-mortem, histopathological examination of brain tissue remains the definitive diagnostic gold standard. The characteristic lesions of non-suppurative encephalitis with demyelination, perivascular lymphocytic cuffing, and intranuclear or intracytoplasmic eosinophilic inclusion bodies (Lentz corpuscles) in neurons and glial cells are pathognomonic [3, 6, 25, 38, 44, 49]. Immunohistochemistry (IHC) using antibodies against CDV nucleoprotein enhances sensitivity and specificity, labeling viral antigen in neurons, astrocytes, and ependymal cells, even in the absence of visible inclusion bodies [3, 6, 57]. In situ hybridization (ISH) can further confirm viral RNA presence in fixed tissues [3]. These techniques are critical for confirming vaccine-associated disease, as demonstrated in cases where PCR and sequencing identified the vaccine strain (Rockborn-like) in the brain of puppies with post-vaccinal encephalitis [25, 43, 45].

In summary, the diagnostic approach to CDV neurologic disease requires a hierarchical strategy. Antigen tests are inadequate for CNS cases. Serology can indicate exposure but is not diagnostic of active neural infection. Molecular detection via RT-PCR or ddPCR on CSF is the most reliable antemortem tool, particularly in chronic cases. Ultimately, histopathology and IHC on brain tissue remain the definitive gold standard, especially for characterizing emerging strains and vaccine-related adverse events.

Phylogenetic and Genetic Diversity of Canine Distemper Virus Strains Associated with Neurologic Disease

Global Lineage Architecture and Neurotropic Potential

The phylogenetic architecture of canine distemper virus (CDV) has undergone extensive clarification over the past two decades, with the hemagglutinin (H) gene serving as the primary molecular target for lineage classification due to its role in host receptor recognition and antigenic variability. The World Organisation for Animal Health (WOAH) recognizes CDV as a globally notifiable pathogen of carnivores, and the expanding diversity of viral lineages directly correlates with the breadth of neurological disease observed across susceptible species. Comprehensive spatial meta-analyses encompassing 457 individual records from 160 published studies have delineated 17 major CDV genotypes circulating worldwide, with Europe/South America-1 (27.4%), Europe-3/Arctic-like (15.5%), Asia-1 (14.5%), America-1 (11.2%), and Europe-2/European Wildlife (7.6%) representing the most prevalent lineages [16]. Importantly, lineage distribution is not merely a geographic curiosity; it underpins differential neurovirulence, host range expansion, and vaccine breakthrough potential.

The Arctic-like lineage, historically associated with high-latitude canid populations, has demonstrated remarkable plasticity in its capacity to cause neurological disease across diverse hosts. In Iran, phylogenetic analysis of the H gene from dogs presenting with both neurologic and non-neurologic clinical forms confirmed that recent isolates cluster within the endemic Arctic-like genetic lineage, with identical genotypic profiles observed regardless of clinical manifestation [2]. This finding suggests that neurovirulence determinants may not be lineage-specific but rather dependent on host factors and viral quasispecies dynamics. Conversely, the intrathacal administration of modified-live Newcastle disease virus vaccine has been evaluated as a therapeutic intervention for CDV encephalitis in dogs, with long-term survival (>3 years) documented in 4 of 13 treated animals, though cerebrospinal fluid cytokine changes could not be definitively attributed to this intervention [61].

Asia-5 Lineage and Neurologic Disease in Felid Conservation

The Asia-5 lineage has emerged as a particularly concerning genotype due to its documented association with fatal neurologic disease in endangered felid populations. Phylogenetic analysis linked fatal neurologic disease in leopards (Panthera pardus) to the Asia-5 lineage in Nepal, where CDV strains circulating among dogs and wild carnivores demonstrated direct transmission pathways through dog predation [1]. This finding is corroborated by serosurveillance data revealing neutralizing antibody seroprevalences of 11% in Bengal tigers and 30% in Indian leopards in Nepal, with more than one-third of seropositive animals exhibiting clinical symptoms and three dying within one week of sampling [17]. The molecular characterization of CDV strains from stray dogs in Kathmandu Valley further confirmed that the Asia-5 lineage is maintained through sylvatic cycles among sympatric carnivores, facilitating recurring spillover events into threatened large carnivore populations [31].

The genetic underpinnings of Asia-5 lineage neurotropism warrant careful examination. Comparative analysis of the H gene from golden jackals (Canis aureus) in Serbia, while belonging to the Arctic lineage rather than Asia-5, revealed a tyrosine (Y) at position 549 of the H protein, a substitution commonly associated with wildlife host adaptation rather than the histidine (H) typically found in domestic dog strains [10]. This Y549H mutation has been independently identified in European Wildlife lineage sequences from northern Italy, where it is associated with increased virulence and neuroinvasiveness [28]. The functional significance of residue 549 lies in its position within the SLAM (signaling lymphocyte activation molecule) receptor binding interface, where amino acid substitutions can alter receptor affinity and potentially facilitate central nervous system (CNS) entry.

America-2 and Novel Lineage Emergence in North American Wildlife

The United States has witnessed the emergence of genetically distinct CDV lineages associated with neurologic disease in both domestic and wild carnivores. A newly described genetic lineage, first detected in 2011 and predominant among clinical submissions from 2011-2013, demonstrated significant divergence from all previously reported genotypes, including America-2, which was considered the dominant circulating lineage in the US [26]. Genomic sequencing confirmed that this novel lineage is highly conserved within its clade, and preliminary serologic testing revealed significantly lower neutralizing antibody titers against this strain compared to vaccine strains, raising concerns about potential vaccine escape [26].

In Michigan, an 11-year investigation of wildlife mortality documented the spread of CDV from the Lower Peninsula into the Upper Peninsula, with three unique wildlife virus strains identified within the America-2 lineage. Two of these strains grouped within a separate subclade, while a third represented a unique sequence type not associated with any existing subclade [49]. Notably, the affected species, raccoons (Procyon lotor), striped skunks (Mephitis mephitis), and gray foxes (Urocyon cinereoargenteus), all exhibited neurologic signs, underscoring the broad host range of these viral variants. Further characterization of a gray fox in New England identified a distinct clade of CDV currently unique to wildlife in that region, co-infected with skunk adenovirus-1 and Listeria monocytogenes, highlighting the complex polymicrobial context in which neurologic CDV infection often occurs [38].

European Wildlife Lineage and Neuropathology in Protected Species

The European Wildlife (EW) lineage has been repeatedly implicated in neurologic disease outbreaks across Central and Southern Europe, affecting species of high conservation priority. In the Czech Republic, phylogenetic analysis of 23 CDV variants from wildlife revealed that 21 belonged to the European lineage and two to the European-Wildlife lineage, with red foxes (Vulpes vulpes) demonstrating the highest positivity rate (28%) and serving as primary maintenance hosts [44]. The detection of CDV in a Eurasian lynx (Lynx lynx) in Germany, the first confirmed case in this endangered species, revealed a classical chronic distemper manifestation with multifocal demyelination in the cerebellum, brain stem, and cervical spinal cord, along with perivascular lymphohistiocytic meningoencephalitis [6]. This case underscores the threat posed by EW lineage strains to remnant Central European lynx populations.

In Italy, CDV strains from the Marsican brown bear (Ursus arctos marsicanus), an isolated population of approximately 50 animals, were characterized as belonging to the Europe Wildlife lineage, identical to strains recovered from sympatric foxes and unvaccinated dogs [47]. The infected bear, despite being subclinical at the time of sampling, highlights the potential for subclinical CNS infection and subsequent recrudescence of neurologic disease during periods of stress. Northern Italian outbreaks in foxes and badgers during 2021 revealed co-circulation of two distinct lineages: Europe/South America-1 in one fox from Modena, resembling variants from a 2018 outbreak, and European Wildlife in animals from Rimini province, with the Y549H mutation present in all sequences [28].

Arctic-like Lineage: Transcontinental Dissemination and Tiger Encephalitis

The Arctic-like lineage has achieved transcontinental distribution, with documented neuropathogenic potential spanning from the Russian Far East to South Asia. Perhaps the most dramatic demonstration of Arctic-like lineage neurotropism occurred in endangered Amur tigers (Panthera tigris altaica) in the Russian Far East, where CDV infection was identified as the cause of fatal encephalitis in multiple individuals between 2001 and 2010. Phylogenetic analysis grouped Amur tiger CDV strains with an Arctic-like strain found in Baikal seals (Phoca sibirica), indicating cross-species transmission between marine and terrestrial mammals [3]. The geographic distribution of positive cases across an expansive area suggested widespread CDV circulation, with direct or indirect mortality estimated at ~1% of the remaining Amur tiger population in 2010 alone.

In domestic dogs from Iran, Arctic-like lineage strains were detected in both neurologic and non-neurologic clinical forms, with respiratory secretions demonstrating the highest viral load in both groups (85% and 80% positivity, respectively) [2]. However, in neurologic cases with negative rapid test results, cerebrospinal fluid (CSF) PCR exhibited the highest sensitivity, establishing CSF as the optimal diagnostic specimen for detecting CNS infection [37]. This diagnostic nuance is critical for understanding the true prevalence of Arctic-like lineage neuroinfection, as peripheral samples may fail to capture virus sequestered within the CNS.

Asia-1 Lineage and Neurologic Disease Across Asian Ecosystems

The Asia-1 genotype has been identified in an expanding range of hosts across Southeast Asia, consistently associated with neurologic manifestations. In Vietnam, CDV strains isolated from small Indian civets (Viverricula indica) during a backyard farm outbreak clustered within the Asia-1 lineage, closely related to strains previously reported from dogs in Thailand, China, and Vietnam [62]. Histopathological examination revealed severe CNS involvement, including necrotic, degenerated, or lost Purkinje cells, eosinophilic intracytoplasmic inclusion bodies, and perivascular cuffing. Similarly, the first confirmed CDV infection in a Javan leopard (Panthera pardus ssp. melas) in Indonesia was attributed to the Asia-1 genotype, with H gene sequencing confirming the lineage [46].

In Brazil, a lethal CDV outbreak in free-ranging black-tufted marmosets (Callithrix penicillata), a neotropical primate species, revealed that viral genomic sequences were closely related to both South American sequences and Vero cell-adapted lineages [7]. The pantropic distribution of CDV antigens in multiple organs of affected marmosets, coupled with neurologic signs and cutaneous lesions, demonstrates the ability of South American lineage strains to breach the primate blood-brain barrier. This finding has profound One Health implications, as non-human primates may serve as sentinels for CDV strains with potential zoonotic risk, a concern the CDC has raised regarding morbillivirus spillover events.

Molecular Determinants of Neurovirulence and Host Adaptation

The genetic diversity underlying CDV neuropathogenesis extends beyond lineage classification to specific molecular determinants within the viral genome. The H protein remains the most extensively characterized determinant, but recent investigations have identified the nucleoprotein (N) as a key virulence factor. In ferret adaptation studies, a common point mutation resulting in an arginine residue at position 519 in the carboxy terminus of the nucleoprotein was identified across all adapted viruses, contributing significantly to pathogenesis [15]. This finding emerged from comparative adaptation experiments demonstrating that pre-existing mutations at low frequencies (genetic memory) within viral quasispecies populations facilitate rapid adaptation to new hosts, including CNS invasion.

The non-structural V protein has been implicated in CDV-induced autophagy via the PI3K/AKT/mTOR signaling pathway, with V protein interacting directly with PI3K to induce cellular autophagy and enhance viral replication [13]. While autophagy primarily facilitates viral replication, its dysregulation within CNS cells may contribute to the demyelinating leukoencephalitis characteristic of chronic distemper encephalitis. This mechanism parallels neurodegenerative processes observed in human multiple sclerosis, as CDV-induced demyelination has been proposed as a relevant animal model for this human condition [12].

The discovery of low-density lipoprotein receptor-related protein 6 (LRP6) as a functional entry receptor for the attenuated Onderstepoort strain, and potentially for wild-type strains in the absence of canonical SLAM and nectin-4 receptors, opens new avenues for understanding CNS entry [21]. Since LRP6 is upregulated in various cancer types and may be expressed on neural cells, CDV strains capable of utilizing this alternative receptor could exhibit enhanced neurotropism. The identification of host E3 ubiquitin ligase Hrd1 as a cellular restriction factor that ubiquitinates and degrades the CDV H protein via the proteasome pathway further highlights the complex host-virus arms race at the molecular level [22].

Implications for Vaccine Design and Disease Surveillance

The genetic diversity of CDV strains causing neurologic disease has direct implications for vaccine efficacy. The neutralizing epitope 238DIEREFDT245, highly conserved in America-1 genotype vaccine strains, is variable across other genotypes, with substitutions such as D238Y and R241G rendering these strains resistant to vaccine-induced neutralizing antibodies [24]. This antigenic variation may explain vaccine breakthrough cases, including post-vaccinal distemper caused by Rockborn-like strains documented in New Zealand puppies [25] and Finland [45], where whole genome sequencing confirmed 99.9% homology between field isolates and vaccine virus, suggesting reversion to virulence.

The detection of CDV in fully vaccinated dogs [27] and wildlife [26] underscores the need for lineage-specific surveillance and potential vaccine strain updates. The WOAH and FAO have emphasized the importance of molecular characterization of circulating strains to inform vaccine development strategies. As CDV continues to expand its host range into previously unexposed primate populations [7] and critically endangered felids [3, 17], the phylogenetic and genetic characterization of neuropathogenic strains must remain a priority for both veterinary public health and conservation medicine.

Therapeutic Strategies and Prognosis for Canine Distemper Neurologic Disease

The management of canine distemper virus (CDV) neurologic disease represents one of the most formidable challenges in contemporary veterinary medicine. Unlike the systemic phase of infection, which may be amenable to supportive care and antiviral intervention, the neurological manifestations of CDV, ranging from myoclonus and ataxia to seizures and progressive encephalomyelitis, carry a notoriously grave prognosis. The therapeutic landscape is characterized by a paucity of specific antiviral agents, reliance on immunomodulation, and a growing body of experimental approaches that, while promising, remain largely outside the standard of care. This section provides an exhaustive analysis of the therapeutic strategies currently employed, the biological rationale underpinning them, and the prognostic indicators that guide clinical decision-making.

The Biological Imperative for Therapeutic Intervention

To understand the therapeutic challenges, one must first appreciate the unique pathobiology of CDV within the central nervous system (CNS). CDV is a morbillivirus that, following initial replication in lymphoid tissues, disseminates hematogenously and invades the CNS via infected mononuclear cells, a mechanism termed the "Trojan horse" strategy. Once within the neuroparenchyma, the virus exhibits a predilection for oligodendrocytes, astrocytes, and neurons, leading to demyelination, neuronal necrosis, and a non-suppurative meningoencephalomyelitis [6, 29]. The virus induces autophagy via the non-structural protein V, which inhibits the PI3K/AKT/mTOR signaling pathway to facilitate viral replication, a molecular mechanism that represents a potential therapeutic target [13]. Furthermore, CDV triggers a profound and prolonged immunosuppression through the depletion of CD4+ Th1 cells and the blockade of interferon and cytokine signaling pathways, which not only exacerbates systemic disease but also permits unchecked viral replication within the CNS [4]. This immunosuppressive state is compounded by the fact that the virus can persist in the brain for extended periods, evading immune clearance and leading to chronic, progressive neurologic deterioration [29, 34]. The World Organisation for Animal Health (WOAH) recognizes CDV as a globally significant pathogen due to its high morbidity, mortality, and broad host range, which includes endangered species, underscoring the need for effective therapeutic strategies.

Conventional Supportive and Symptomatic Therapies

Historically, the management of CDV neurologic disease has been largely palliative, focusing on controlling seizures, reducing intracranial inflammation, and providing nutritional support. Anticonvulsants such as phenobarbital are commonly employed to manage seizure activity, but their effect is purely symptomatic and does not alter the underlying viral pathogenesis. A recent clinical trial evaluating the combination of phenobarbital (2.5 mg/kg every 12 hours) and prednisolone (0.55 mg/kg every 12 hours) in 25 dogs with confirmed neurologic CDV reported a dismal recovery rate of only 8%, with 18 dogs dying or being euthanized [35]. While phenobarbital demonstrated some efficacy in controlling seizures, the addition of prednisolone, a corticosteroid intended to mitigate inflammatory demyelination, conferred no survival benefit. This finding aligns with the understanding that corticosteroids may exacerbate immunosuppression in a host already severely immunocompromised by the virus, potentially facilitating viral persistence. The study’s authors concluded that prednisolone offers limited benefit for neurologic CDV, and its routine use cannot be recommended [35]. This underscores a critical therapeutic paradox: the very agents used to control inflammation may hinder viral clearance.

Immunomodulatory and Antiviral Approaches: The Promise and Pitfalls

Given the central role of immune dysfunction in CDV pathogenesis, immunomodulatory therapies have been explored with variable success. The use of type I interferons, which are critical components of the innate antiviral response, has been proposed based on in vitro evidence that attenuated CDV strains induce a robust interferon response in alveolar macrophages, whereas virulent field strains suppress this pathway [32]. However, clinical trials in dogs have failed to demonstrate consistent efficacy, likely due to the advanced stage of immunosuppression at the time of diagnosis. The concept of "therapeutic vaccination" using heterologous viruses has also been investigated. Two studies evaluated the intrathecal injection of a modified-live Newcastle disease virus vaccine (NDV-MLV) in dogs with CDV encephalitis. The rationale was that NDV would induce a non-specific antiviral state through interferon induction and immune stimulation. In one study, 6 of 13 dogs survived to follow-up, with 4 surviving long-term (>3 years), but the authors could not attribute the survival to the NDV-MLV therapy, as cerebrospinal fluid cytokine profiles did not change significantly [61]. A second, smaller study reported a 22.2% recovery rate, but the sample size was too limited to draw definitive conclusions [52]. The consensus from these investigations is that intrathecal NDV-MLV cannot be recommended as a standard therapy, and the risk of exacerbating CNS inflammation outweighs any potential benefit.

Nanotechnology: Silver Nanoparticles as a Targeted Antiviral Strategy

A paradigm shift in the therapeutic approach to CDV neurologic disease has emerged from the application of nanotechnology. Silver nanoparticles (AgNPs) possess broad-spectrum antiviral properties, thought to be mediated by direct interaction with viral envelope glycoproteins, inhibition of viral entry, and disruption of viral replication. A landmark randomized clinical trial evaluated the efficacy and safety of 3% oral and nasal AgNPs in 207 naturally infected dogs, stratified into non-neurologic and neurologic groups [50]. The results were striking: in dogs with non-neurologic distemper, the survival rate in the AgNP-treated group was 84.6% (44/52) compared to 15.2% (7/46) in the supportive care-only control group. Even more remarkably, in dogs with clinical signs of neurologic distemper, a group historically considered to have a near-zero survival rate, the AgNP-treated group achieved a survival rate of 65.6% (38/58), while all 51 dogs in the control group died [50]. Furthermore, a significant proportion of the surviving neurologic dogs recovered without sequelae, a finding unprecedented in the literature. No adverse reactions were detected, suggesting a favorable safety profile. The mechanism of action in the CNS is hypothesized to involve the ability of nanoparticles to cross the blood-brain barrier, where they may directly inhibit viral replication within neurons and glial cells. While these results require independent replication and long-term follow-up, they represent the most promising therapeutic advance for CDV neurologic disease in decades and suggest that AgNP therapy could be considered a targeted treatment for severely affected dogs [50].

Emerging Biologics: Monoclonal Antibodies and DNA Vaccines

The development of specific neutralizing antibodies represents a logical therapeutic strategy for a viral disease where humoral immunity is critical for clearance. Using single B cell antibody technology, researchers have recently generated whole-canine monoclonal antibodies (mAbs) against the CDV hemagglutinin (H) protein [63]. Among seven mAbs screened, two, designated D16 and F53, exhibited high binding affinity and potent neutralizing activity against CDV. In an in vivo challenge model, D16 demonstrated effective therapeutic protection in dogs subjected to a lethal dose of CDV [63]. This approach offers a promising new strategy for passive immunotherapy, particularly in acute cases where rapid viral neutralization is required. However, the utility of mAbs in established neurologic disease remains uncertain, as the blood-brain barrier may limit antibody penetration into the CNS parenchyma. Additionally, the high cost of production and the need for parenteral administration may limit widespread clinical application.

DNA vaccine technology has also been explored as a therapeutic modality. A study in ferrets evaluated a DNA vaccine co-expressing codon-optimized CDV hemagglutinin and ferret interferon-γ as a molecular adjuvant [64]. While the vaccine elicited neutralizing antibodies and cytokine responses, and provided partial protection (75% survival) against lethal challenge, it could not completely prevent viremia or virus shedding [64]. This suggests that DNA vaccines may be more suitable for prophylactic use in high-risk populations rather than as a therapeutic intervention for established neurologic disease.

Prognostic Indicators and Clinical Outcomes

The prognosis for dogs with CDV neurologic disease is influenced by a constellation of factors, including the temporal onset of signs, the specific neurologic deficits, and the host’s immune status. A large retrospective study identified that younger dogs, and those of the Shih Tzu and Lhasa Apso breeds, have a significantly increased likelihood of developing neurologic signs following CDV infection [30]. The median survival time in this cohort was 754 days, with a mortality rate of 47.06%, indicating that while some dogs can survive for extended periods, the lethality remains substantial [30]. The presence of myoclonus, rhythmic, involuntary muscle contractions, is a hallmark of chronic CDV encephalitis and, while often permanent, is not necessarily a poor prognostic indicator for survival if other neurologic signs are absent. Conversely, the development of generalized seizures, progressive ataxia, or altered mentation portends a grave outcome, particularly if these signs appear acutely during the systemic phase of infection [35].

The duration of viral RNA excretion is another critical prognostic factor. In shelter dogs, the median duration of a positive RT-PCR test was 34 days, with 25% of dogs still excreting viral RNA after 62 days [34]. Importantly, infectious virus was isolated only within the first two weeks of monitoring, coinciding with peak viral RNA excretion. This suggests that the end of infectious risk may be gauged by the decline in viral load, and that dogs with prolonged RNA excretion are not necessarily contagious, which has significant implications for shelter management and euthanasia decisions [34]. The detection of CDV in cerebrospinal fluid (CSF) by RT-PCR is a more sensitive diagnostic indicator in neurologic cases than blood or mucosal swabs, particularly in dogs that have recovered from systemic signs but later develop neurologic disease [2, 37]. A positive CSF PCR in a dog with neurologic signs confirms active CNS infection and is associated with a poorer prognosis, as it indicates viral persistence within the brain [37].

The Conservation Imperative: Therapeutic Considerations for Wildlife

The therapeutic strategies discussed above are primarily derived from studies in domestic dogs, but their extrapolation to wildlife, where CDV poses an existential threat to endangered species, is fraught with ethical and logistical challenges. Outbreaks in Amur tigers, leopards, and African wild dogs have resulted in mortality rates exceeding 30%, and in some cases, up to 94% [3, 14, 17]. Vaccination of captive and free-ranging wildlife with live-attenuated CDV vaccines has been attempted, but safety concerns remain. A study in African wild dog pups reported that 81% generated protective titers after initial vaccination, but one pup died of suspected vaccine-induced neurologic disease within 17 days [53]. Similarly, post-vaccinal distemper has been documented in domestic puppies, where the Rockborn vaccine strain was identified in the brains of puppies that developed fatal encephalitis [25, 43, 45]. These cases highlight the risk of reversion to virulence in modified-live virus vaccines, particularly in immunocompromised or genetically susceptible individuals. The WOAH and the Food and Agriculture Organization (FAO) emphasize the need for rigorous safety testing of vaccines intended for use in wildlife, and the development of non-replicating or recombinant vaccines is a priority for conservation medicine.

Future Directions and Unmet Needs

The therapeutic armamentarium for CDV neurologic disease remains woefully inadequate. The success of silver nanoparticles in clinical trials warrants urgent validation in multi-center, placebo-controlled studies, and the mechanisms by which they exert antiviral effects in the CNS require elucidation. The identification of host factors that restrict viral replication, such as the E3 ubiquitin ligase Hrd1, which targets the CDV H protein for proteasomal degradation, opens new avenues for host-directed therapy [22]. Additionally, the discovery that the attenuated Onderstepoort strain of CDV uses low-density lipoprotein receptor-related protein 6 (LRP6) as an entry receptor in cancer cells [21] raises the intriguing possibility that oncolytic CDV strains could be engineered for therapeutic use in canine neoplasia, though this is distinct from treating distemper itself. The development of safe, effective, and affordable antiviral agents, whether small molecules, nanoparticles, or biologics, remains the most pressing unmet need. Until such agents are available, the cornerstone of management will remain prevention through vaccination, early diagnosis using sensitive molecular techniques such as droplet digital PCR [58], and aggressive supportive care. The prognosis for a dog with established neurologic CDV is guarded to poor, but the advent of nanotechnology and monoclonal antibody therapy offers a glimmer of hope in an otherwise bleak therapeutic landscape.

Prevention and Control of Canine Distemper Neurologic Disease: Vaccination and Wildlife Management

The prevention and control of canine distemper virus (CDV)-induced neurologic disease represent a formidable challenge at the intersection of veterinary medicine, conservation biology, and wildlife ecology. The pathophysiological complexity of CDV encephalitis, coupled with the virus’s extraordinary host range and its ability to establish persistent infections in reservoir populations, demands a multifaceted strategy that extends far beyond routine domestic dog vaccination. Effective mitigation requires a rigorous understanding of vaccine immunology, the limitations of current biologics, the ecological dynamics of viral maintenance in wildlife, and the implementation of targeted management interventions that address the domestic–wildlife interface. This section provides an exhaustive analysis of these interconnected domains, drawing upon the most recent and authoritative evidence to inform a comprehensive framework for controlling CDV neurologic disease.

Vaccination Strategies for Domestic Dogs: Cornerstone and Caveats

Vaccination remains the single most effective intervention for preventing CDV infection and its neurologic sequelae in domestic dogs. The widespread use of modified-live virus (MLV) vaccines, primarily derived from the Onderstepoort or Rockborn strains, has dramatically reduced the incidence of clinical distemper in regions with high vaccination coverage [8, 16]. These vaccines induce robust humoral and cell-mediated immunity, targeting the hemagglutinin (H) and fusion (F) proteins, which are critical for viral attachment and entry. Neutralizing antibodies against the H protein are considered the primary correlate of protection, preventing viral dissemination to the central nervous system (CNS) [24, 63]. However, the emergence of neurologic disease in vaccinated animals, as documented in multiple recent studies, underscores critical gaps in vaccine efficacy and raises concerns about antigenic drift, vaccine strain safety, and the impact of maternal antibody interference [25, 27, 30].

A growing body of evidence indicates that currently circulating wild-type CDV strains may be antigenically distinct from the vaccine strains used in commercial products. Riley and Wilkes [26] identified a novel CDV lineage in the United States that exhibited significant serologic differences from the America-1 (Onderstepoort) vaccine strain, with vaccinated dogs showing markedly lower neutralizing antibody titers against this emerging strain. This finding is corroborated by studies in South America, where Feijóo et al. [27] demonstrated that vaccinated dogs in Uruguay succumbed to neurologic distemper caused by wild-type strains belonging to the EU1/SA1 lineage, which are not represented in available vaccines. Similarly, in Iran, Mojtahedzadeh et al. [2] found that both neurologic and non-neurologic forms of CDV in unvaccinated dogs were caused by Arctic-like lineage strains, further emphasizing the genetic divergence between vaccine and field strains. These observations suggest that vaccine-induced immunity may be insufficient to prevent infection and subsequent CNS invasion by heterologous viral lineages, a phenomenon that has profound implications for vaccine design and booster schedules.

The phenomenon of post-vaccinal distemper, although rare, represents a critical safety concern that must be acknowledged in any comprehensive prevention strategy. Multiple case series have now confirmed that MLV CDV vaccines can, under certain circumstances, revert to virulence and cause fatal neurologic disease. Gulliver et al. [25] reported nine cases of neurologic disease and sudden death in 8–13-week-old puppies in New Zealand following vaccination with a Rockborn-like strain, with whole-genome sequencing confirming 99.9% homology between the vaccine virus and the agent isolated from affected tissues. Rätsep and Ojkić [43] described a similar case in a 14-week-old puppy in Canada, where the Rockborn vaccine strain was identified in the brain despite the absence of classic histologic lesions such as demyelination or inclusion bodies. Pekkarinen et al. [45] documented post-vaccinal distemper in two separate litters, with one litter exhibiting atypical lymphoid necrosis and the other developing encephalitis months after vaccination. These cases highlight the potential for vaccine strain reversion, particularly in immunocompromised individuals or those with undiagnosed genetic predispositions. The World Organisation for Animal Health (WOAH) and national veterinary authorities recommend that any neurologic signs occurring within six weeks of MLV CDV vaccination be thoroughly investigated, as this temporal association may indicate vaccine-induced disease [25, 45].

Vaccination of Captive and Free-Ranging Wildlife: Balancing Benefits and Risks

The application of CDV vaccination to wildlife populations, particularly endangered species, is a highly contentious and complex issue. While the theoretical benefits of protecting vulnerable populations from lethal neurologic disease are substantial, the practical and ethical challenges are formidable. The use of MLV vaccines in non-canid species carries a well-documented risk of inducing disease, as these vaccines were developed and safety-tested primarily in domestic dogs. Despite this, the urgent need to protect species such as the Amur tiger, African wild dog, and various felid species has driven the exploration of vaccination strategies in both captive and free-ranging settings [3, 29, 53].

For captive wildlife, the use of killed or recombinant vaccines is generally preferred over MLV products to minimize the risk of vaccine-induced disease. Blythe et al. [29] reported the first documented case of chronic CDV encephalomyelitis in a Bengal tiger and recommended the use of killed vaccines for large felids when exposure risk is high. However, the immunogenicity of killed vaccines is often inferior to that of MLV vaccines, and multiple doses may be required to achieve protective antibody titers. In free-ranging populations, logistical constraints make such multi-dose regimens impractical. The situation is further complicated by the fact that many endangered species, such as the Amur tiger and the Javan leopard, have been shown to be susceptible to CDV neurologic disease, with mortality rates that can threaten population viability [3, 46]. Seimon et al. [3] demonstrated that CDV directly or indirectly killed approximately 1% of the Amur tiger population in the Russian Far East in 2010, with infected animals exhibiting severe nonsuppurative encephalitis and demyelination. Similarly, Sadaula et al. [1] reported fatal neurologic disease in leopards in Nepal caused by the Asia-5 lineage, which is prevalent in sympatric dog populations.

The most compelling evidence for the feasibility of wildlife vaccination comes from studies of African wild dogs (Lycaon pictus). Gieling et al. [53] evaluated the use of a commercially available MLV CDV vaccine (Vanguard™ Plus 5/L) in 16 captive African wild dog pups. Remarkably, 81% of pups generated protective antibody titers after the initial vaccination, and 100% achieved protective immunity following a booster dose. However, one pup died of suspected vaccine-induced neurologic disease within 17 days of the first vaccination, highlighting the inherent risk. The authors concluded that the protective benefit of vaccination likely outweighs the risk of vaccine-induced disease in this critically endangered species, particularly given the high mortality associated with natural CDV infection. This risk-benefit calculus must be carefully evaluated on a species-by-species and population-by-population basis, with input from veterinary epidemiologists, conservation biologists, and regulatory authorities such as the WOAH and the International Union for Conservation of Nature (IUCN).

Wildlife Management and Reservoir Control: Breaking the Transmission Cycle

The prevention of CDV neurologic disease in wildlife cannot be achieved through vaccination alone; it requires a comprehensive wildlife management strategy that addresses the ecological drivers of viral maintenance and spillover. Domestic dogs (Canis lupus familiaris) are widely recognized as the primary reservoir for CDV, and their populations serve as a continuous source of infection for sympatric wildlife [1, 14, 16, 19]. The systematic review by Angwenyi et al. [14] found that 61% of studies investigating the role of domestic dogs concluded that they act as reservoirs or sources of CDV for African wildlife, with mortality rates in affected wildlife populations ranging from 30% to 94%. In Nepal, McDermott et al. [19] reported an 80% seroprevalence of CDV in free-roaming dogs surrounding Chitwan National Park, indicating intense viral circulation in the domestic dog population that poses a direct threat to Bengal tigers and leopards. Bodgener et al. [17] further demonstrated that leopards in Nepal frequently predate on domestic dogs, providing a plausible mechanism for viral transmission from the reservoir to the endangered felid population.

Effective control of CDV in the domestic dog reservoir requires a combination of mass vaccination, population management, and surveillance. The WOAH recommends that vaccination coverage of at least 70% of the dog population is necessary to achieve herd immunity and interrupt viral transmission. In many regions where wildlife reserves are adjacent to human settlements, this target is far from being met. Free-roaming dog neutering and vaccination programs, as advocated by McDermott et al. [19], can serve as a dual-purpose intervention, reducing both the population size and the proportion of susceptible individuals. Such programs must be sustained over multiple years to be effective, as the high turnover rate of free-roaming dog populations can rapidly erode vaccination coverage. Furthermore, the genetic characterization of circulating CDV strains in domestic dogs, as performed by Manandhar et al. [31] in Nepal, is essential for understanding the dynamics of viral spillover into wildlife. Their identification of the Asia-5 lineage in both stray dogs and wild carnivores underscores the interconnectedness of the domestic–wildlife interface and the need for integrated surveillance.

Surveillance of wildlife populations for CDV infection is a critical but often neglected component of prevention and control. Passive surveillance, based on the testing of animals found dead or exhibiting neurologic signs, has been the primary method for detecting CDV in wildlife [41, 44, 49]. Fitzgerald et al. [49] documented the geographic spread of CDV in wild carnivores in Michigan over an 11-year period, identifying raccoons, striped skunks, and gray foxes as the most frequently infected species. Taylor et al. [41] analyzed 45 years of passive surveillance data from the southeastern United States and found that CDV cases in raccoons and gray foxes were more likely to occur in areas of medium to high human population density, suggesting that suburban habitats with high mesocarnivore densities serve as hotspots for viral transmission. These findings have direct implications for targeted management interventions, such as trap-neuter-vaccinate-release programs for raccoons in high-risk areas.

The development of portable, point-of-care diagnostic tools has the potential to revolutionize CDV surveillance in remote and resource-limited settings. Brown et al. [55] validated a handheld qPCR platform (Biomeme two3™) for the detection of CDV in wildlife, demonstrating comparable sensitivity to laboratory-based methods for positive control samples. Although the platform showed decreased sensitivity (higher Ct values) when testing animal samples, its ability to provide rapid, on-site results eliminates the need for sample transport and can empower wildlife health professionals to make real-time management decisions. The integration of such technologies into routine surveillance programs, combined with spatial epidemiological modeling using remote sensing data, as proposed by Carella et al. [42], can enable the prediction of CDV outbreak risk based on landscape fragmentation and habitat connectivity. This One Health approach, which recognizes the inextricable links between human, animal, and environmental health, is essential for the long-term prevention and control of CDV neurologic disease in both domestic and wild carnivore populations.

References

[1] Sadaula A, Manandhar P, Shrestha BK, Thapa PJ, Nepali S, Joshi JD, et al.. Phylogenetic analysis linked fatal neurologic disease in leopards (Panthera pardus) to Asia-5 lineage of canine distemper virus in Nepal. Virus Research. 2024. DOI: https://doi.org/10.1016/j.virusres.2024.199463

[2] Mojtahedzadeh SM, Jamshidi S, Langroudi AG, Vahedi SM, Tamai IA, Akbarein H, et al.. Molecular Detection of Canine Distemper Virus Among Dogs Showing Neurologic and Non-neurologic Forms of Disease. Iranian Journal of Veterinary Medicine. 2024. DOI: https://doi.org/10.32598/ijvm.18.2.1005294

[3] Seimon T, Miquelle D, Chang TY, Newton A, Korotkova I, Ivanchuk GV, et al.. Canine Distemper Virus: an Emerging Disease in Wild Endangered Amur Tigers (Panthera tigris altaica). mBio. 2013. DOI: https://doi.org/10.1128/mBio.00410-13

[4] Céspedes PF, Cruz P, Navarro C. Modulación de la respuesta inmune durante la infección por virus distemper canino: implicancias terapéuticas y en el desarrollo de vacunas. Archivos De Medicina Veterinaria. 2010. DOI: https://doi.org/10.4067/S0301-732X2010000200003

[5] Laksono B, Roelofs D, Comvalius A, Schmitz K, Rijsbergen L, Geers D, et al.. Infection of ferrets with wild type-based recombinant canine distemper virus overwhelms the immune system and causes fatal systemic disease. Msphere. 2023. DOI: https://doi.org/10.1128/msphere.00082-23

[6] Lombardo MS, Mirolo M, Brandes F, Osterhaus A, Schütte K, Ludlow M, et al.. Case report: Canine distemper virus infection as a cause of central nervous system disease in a Eurasian lynx (Lynx lynx). Frontiers in Veterinary Science. 2023. DOI: https://doi.org/10.3389/fvets.2023.1251018

[7] Campos BHd, Santos DDD, Duarte JR, Amaral VHB, Figueiredo C, Vieira AD, et al.. Lethal Canine Distemper Virus (Morbillivirus canis) Outbreak in Free-Ranging Black-Tufted Marmosets (Callithrix penicillata) in Brazil: Clinical, Pathological, Genotypical Evaluation, and Assessment of Viral Tropism. Transboundary and Emerging Diseases. 2025. DOI: https://doi.org/10.1155/tbed/4701926

[8] Rivera-Martínez A, Rodríguez-Alarcón C, Adame-Gallegos J, Laredo-Tiscareño S, Luna-Santillana EDd, Hernández-Triana L, et al.. Canine Distemper Virus: Origins, Mutations, Diagnosis, and Epidemiology in Mexico. Life. 2024. DOI: https://doi.org/10.3390/life14081002

[9] Burrell CE, Anchor C, Ahmed N, Landolfi J, Jarosinski K, Terio K. Characterization and Comparison of SLAM/CD150 in Free-Ranging Coyotes, Raccoons, and Skunks in Illinois for Elucidation of Canine Distemper Virus Disease. Pathogens. 2020. DOI: https://doi.org/10.3390/pathogens9060510

[10] Glišić D, Kuručki M, Ćirović D, Šolaja S, Mirčeta J, Milićević V. Molecular analysis of canine distemper virus H gene in the golden jackal (Canis aureus) population from Serbia. BMC Veterinary Research. 2024. DOI: https://doi.org/10.1186/s12917-024-04284-5

[11] Zhou H, Li H, Sun X, Lin J, Zhang C, Zhao J, et al.. Rapid diagnosis of Canine respiratory coronavirus, Canine influenza virus, Canine distemper virus and Canine parainfluenza virus with a Taqman probe-based multiplex real-time PCR.. Journal of Virological Methods. 2024. DOI: https://doi.org/10.1016/j.jviromet.2024.114960

[12] Gutiérrez M, Delucchi L, Bielli A, Verdes J. Prolonged Visual Evoked Potential Latencies in Dogs Naturally Infected with Canine Distemper Virus.. Viruses. 2024. DOI: https://doi.org/10.3390/v16111721

[13] Tian X, Zhang R, Yi S, Chen Y, Jiang Y, Zhang X, et al.. Non-Structural Protein V of Canine Distemper Virus Induces Autophagy via PI3K/AKT/mTOR Pathway to Facilitate Viral Replication. International Journal of Molecular Sciences. 2024. DOI: https://doi.org/10.3390/ijms26010084

[14] Angwenyi S, Rooney N, Eisler M. ARE DOMESTIC DOGS (CANIS FAMILIARIS) THE FAMILY SCAPEGOATS? A SYSTEMATIC REVIEW OF CANINE DISTEMPER VIRUS IN AFRICAN WILDLIFE, 1978–2021. Journal of Wildlife Diseases. 2024. DOI: https://doi.org/10.7589/JWD-D-24-00017

[15] Siering O, Langbein M, Herrmann M, Wittwer K, Messling Vv, Sawatsky B, et al.. Genetic diversity accelerates canine distemper virus adaptation to ferrets. Journal of Virology. 2024. DOI: https://doi.org/10.1128/jvi.00657-24

[16] Wipf A, Pérez-Cutillas P, Ortega N, Huertas-López A, Martínez-Carrasco C, Candela MG. Geographical Distribution of Carnivore Hosts and Genotypes of Canine Distemper Virus (CDV) Worldwide: A Scoping Review and Spatial Meta-Analysis. Transboundary and Emerging Diseases. 2025. DOI: https://doi.org/10.1155/tbed/6632068

[17] Bodgener J, Sadaula A, Thapa PJ, Shrestha B, Gairhe K, Subedi S, et al.. Canine Distemper Virus in Tigers (Panthera tigris) and Leopards (P. pardus) in Nepal. Pathogens. 2023. DOI: https://doi.org/10.3390/pathogens12020203

[18] Prpić J, Lojkić I, Keros T, Krešić N, Jemeršić L. Canine Distemper Virus Infection in the Free-Living Wild Canines, the Red Fox (Vulpes vulpes) and Jackal (Canis aureus moreoticus), in Croatia. Pathogens. 2023. DOI: https://doi.org/10.3390/pathogens12060833

[19] McDermott I, Gilbert M, Shah M, Sadaula A, Anderson N. Seroprevalence of canine distemper virus (CDV) in the free-roaming dog (Canis familiaris) population surrounding Chitwan National Park, Nepal. PLoS ONE. 2023. DOI: https://doi.org/10.1371/journal.pone.0281542

[20] Wang H, Guo H, Hein V, Xu Y, Yu S, Wang X. The evolutionary dynamics history of canine distemper virus through analysis of the hemagglutinin gene during 1930–2020. Zeitschrift f\ ur Jagdwissenschaft. 2023. DOI: https://doi.org/10.1007/s10344-023-01685-z

[21] Gradauskaite V, Inglebert M, Doench JG, Scherer M, Dettwiler M, Wyss M, et al.. LRP6 Is a Functional Receptor for Attenuated Canine Distemper Virus. mBio. 2023. DOI: https://doi.org/10.1128/mbio.03114-22

[22] Wang W, Bi Z, Song S. Host E3 ligase Hrd1 ubiquitinates and degrades H protein of canine distemper virus to inhibit viral replication. Veterinary Research. 2023. DOI: https://doi.org/10.1186/s13567-023-01163-z

[23] Roelofs D, Schmitz K, Amerongen Gv, Rijsbergen L, Laksono B, Comvalius A, et al.. Inoculation of raccoons with a wild-type-based recombinant canine distemper virus results in viremia, lymphopenia, fever, and widespread histological lesions. Msphere. 2023. DOI: https://doi.org/10.1128/msphere.00144-23

[24] Wang W, Bi Z, Liu Y, Xia X, Qian J, Tan Y, et al.. Development of a monoclonal antibody recognizing novel linear neutralizing epitope on H protein of canine distemper virus vaccine strains (America-1 genotype).. International Journal of Biological Macromolecules. 2023. DOI: https://doi.org/10.1016/j.ijbiomac.2023.125584

[25] Gulliver E, Taylor H, Eames M, Chernyavtseva A, Jáuregui R, Wilson A, et al.. Investigation of post-vaccinal canine distemper involving the Rockborn-like strain in nine puppies in New Zealand. New Zealand Veterinary Journal. 2025. DOI: https://doi.org/10.1080/00480169.2025.2481896

[26] Riley M, Wilkes R. Sequencing of emerging canine distemper virus strain reveals new distinct genetic lineage in the United States associated with disease in wildlife and domestic canine populations. Virology Journal. 2015. DOI: https://doi.org/10.1186/s12985-015-0445-7

[27] Feijóo G, Yamasaki K, Delucchi L, Verdes J. Central nervous system lesions caused by canine distemper virus in 4 vaccinated dogs. Journal of Veterinary Diagnostic Investigation. 2021. DOI: https://doi.org/10.1177/10406387211009210

[28] Trogu T, Castelli A, Canziani S, Tolini C, Carrera M, Sozzi E, et al.. Detection and Molecular Characterization of Canine Distemper Virus in Wildlife from Northern Italy. Pathogens. 2022. DOI: https://doi.org/10.3390/pathogens11121557

[29] Blythe LL, Schmitz JA, Roelke M, Skinner S. Chronic encephalomyelitis caused by canine distemper virus in a Bengal tiger.. Journal of the American Veterinary Medical Association. 1983. DOI: https://doi.org/10.2460/javma.1983.183.11.1159

[30] Freire HL, Iara ÍHN, Ribeiro LSR, Gonçalves PAO, Matta DH, Torres B. Neurological Manifestation of Canine Distemper Virus: Increased Risk in Young Shih Tzu and Lhasa Apso with Seasonal Prevalence in Autumn. Viruses. 2025. DOI: https://doi.org/10.3390/v17060820

[31] Manandhar P, Napit R, Pradhan S, Rajbhandari PG, Moravek J, Joshi P, et al.. Phylogenetic characterization of canine distemper virus from stray dogs in Kathmandu Valley. Virology Journal. 2023. DOI: https://doi.org/10.1186/s12985-023-02071-6

[32] Pöpperl P, Chludzinski E, Stoff M, Geffers R, Ludlow M, Beineke A. Attenuation of canine distemper virus leads to a potent antiviral innate immune response with restricted infection of alveolar macrophages. Journal of Virology. 2025. DOI: https://doi.org/10.1128/jvi.01761-25

[33] Chludzinski E, Ciurkiewicz M, Stoff M, Klemens J, Krüger J, Shin D, et al.. Canine Distemper Virus Alters Defense Responses in an Ex Vivo Model of Pulmonary Infection. Viruses. 2023. DOI: https://doi.org/10.3390/v15040834

[34] Allen C, Ellis A, Liang R, Lim A, Newbury SP. Prolonged persistence of canine distemper virus RNA, and virus isolation in naturally infected shelter dogs. PLoS ONE. 2023. DOI: https://doi.org/10.1371/journal.pone.0280186

[35] Sarchahi AA, Arbabi M, Mohebalian H. Effects of Phenobarbital and Prednisolone on Neurological Signs of Canine Distemper. Veterinary Medicine and Science. 2025. DOI: https://doi.org/10.1002/vms3.70479

[36] Chludzinski E, Klemens J, Ciurkiewicz M, Geffers R, Pöpperl P, Stoff M, et al.. Phenotypic and Transcriptional Changes of Pulmonary Immune Responses in Dogs Following Canine Distemper Virus Infection. International Journal of Molecular Sciences. 2022. DOI: https://doi.org/10.3390/ijms231710019

[37] Sarchahi AA, Arbabi M, Mohebalian H. Detection of canine distemper virus in cerebrospinal fluid, whole blood and mucosal specimens of dogs with distemper using RT‐PCR and immunochromatographic assays. Veterinary Medicine and Science. 2022. DOI: https://doi.org/10.1002/vms3.790

[38] Needle D, Marr JL, Park CJ, Andam CP, Wise A, Maes R, et al.. Concurrent Infection of Skunk Adenovirus-1, Listeria monocytogenes, and a Regionally Specific Clade of Canine Distemper Virus in One Gray Fox (Urocyon cinereoargenteus) and Concurrent Listeriosis and Canine Distemper in a Second Gray Fox. Pathogens. 2020. DOI: https://doi.org/10.3390/pathogens9070591

[39] Woolf A, Gremillion-Smith C, Evans R. Evidence of canine distemper virus infection in skunks negative for antibody against rabies virus.. Journal of the American Veterinary Medical Association. 1986. DOI: https://doi.org/10.2460/javma.1986.189.09.1086

[40] Dorsch M, Cesar D, Bullock H, Uzal F, Ritter J, Giannitti F. Fatal Toxoplasma gondii myocarditis in an urban pet dog.. Veterinary Parasitology: Regional Studies and Reports. 2021. DOI: https://doi.org/10.1016/j.vprsr.2021.100659

[41] Taylor K, Wilson J, Park AW, Nemeth N, Yabsley M, Fenton H, et al.. TEMPORAL AND SPATIAL PATTERNS IN CANINE DISTEMPER VIRUS CASES IN WILDLIFE DIAGNOSED AT THE SOUTHEASTERN COOPERATIVE WILDLIFE DISEASE STUDY, 1975–2019. Journal of Wildlife Diseases. 2021. DOI: https://doi.org/10.7589/JWD-D-20-00212

[42] Carella E, Orusa T, Viani A, Meloni D, Borgogno-Mondino E, Orusa R. An Integrated, Tentative Remote-Sensing Approach Based on NDVI Entropy to Model Canine Distemper Virus in Wildlife and to Prompt Science-Based Management Policies. Animals. 2022. DOI: https://doi.org/10.3390/ani12081049

[43] Rätsep E, Ojkić D. Canine distemper virus infection of vaccinal origin in a 14-week-old puppy. Journal of Veterinary Diagnostic Investigation. 2024. DOI: https://doi.org/10.1177/10406387241229436

[44] Kličková E, Černíková L, Dumondin A, Bártová E, Budíková M, Sędłak K. Canine Distemper Virus in Wild Carnivore Populations from the Czech Republic (2012–2020): Occurrence, Geographical Distribution, and Phylogenetic Analysis. Life. 2022. DOI: https://doi.org/10.3390/life12020289

[45] Pekkarinen HM, Karkamo V, Vainio-Siukola KJ, Hautaniemi M, Kinnunen P, Gadd T, et al.. Post-vaccinal distemper-like disease in two dog litters with confirmed infection of vaccine virus strain.. Comparative Immunology, Microbiology & Infectious Diseases. 2023. DOI: https://doi.org/10.1016/j.cimid.2023.102114

[46] Rahman DA, Saepuloh U, Santosa Y, Darusman HS, Pinondang IMR, Kindangen AS, et al.. Molecular diagnosis with the corresponding clinical symptoms of canine distemper virus infection in javan leopard (Panthera pardus ssp. melas). Heliyon. 2022. DOI: https://doi.org/10.1016/j.heliyon.2022.e11341

[47] Francesco CDD, Smoglica C, Pirro VD, Cafini F, Gentile L, Marsilio F. Molecular Detection and Phylogenetic Analysis of Canine Distemper Virus in Marsican Brown Bear (Ursus arctos marsicanus). Animals. 2022. DOI: https://doi.org/10.3390/ani12141826

[48] Villalba-Briones R, Barros-Diaz C, Gallo-Pérez A, Blasco-Carlos M, Molineros EB. First description of sarcoptic mange in a wild coati (Nasua narica), in Ecuador, and cooccurrence of canine distemper virus. Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria. 2022. DOI: https://doi.org/10.1590/S1984-29612022002

[49] Fitzgerald S, Melotti J, Cooley T, Wise A, Maes R, O'Brien D. GEOGRAPHIC SPREAD OF CANINE DISTEMPER IN WILD CARNIVORES IN MICHIGAN, USA: PATHOLOGY AND EPIDEMIOLOGY, 2008–18. Journal of Wildlife Diseases. 2022. DOI: https://doi.org/10.7589/JWD-D-21-00184

[50] Gastelum-Leyva F, Pena-Jasso A, Alvarado-Vera M, Plascencia-López I, Patrón-Romero L, Loera-Castañeda V, et al.. Evaluation of the Efficacy and Safety of Silver Nanoparticles in the Treatment of Non-Neurological and Neurological Distemper in Dogs: A Randomized Clinical Trial. Viruses. 2022. DOI: https://doi.org/10.3390/v14112329

[51] Curti MC, Arias MB, Zanutto MS. Avaliação de um kit de imunoensaio cromatográfico para detecção do antígeno do vírus da cinomose em cães com sinais sistêmicos ou neurológicos da doença. Semina-ciencias Agrarias. 2012. DOI: https://doi.org/10.5433/1679-0359.2012V33N6P2383

[52] Sarchahi AA, Mohebalian H, Arbabi M. Evaluation of Newcastle disease virus vaccine effectiveness in dogs with neurological signs of canine distemper. Veterinary Research Forum. 2022. DOI: https://doi.org/10.30466/vrf.2021.531605.3194

[53] Gieling R, Schmidt‐Küntzel A, Flores-Pineda K, Bailey M, Rooney N, Marker L. EFFECTIVE ANTIBODY RESPONSE OF AFRICAN WILD DOGS (LYCAON PICTUS) TO CANINE DISTEMPER VACCINATION WITH A LIVE ATTENUATED VACCINE. Journal of zoo and wildlife medicine. 2025. DOI: https://doi.org/10.1638/2023-0088

[54] Mohan N, Rani N, Suresh K, Srinivas M, Megha P, Vishnudas K. Comparative Analysis of Diagnostic Methods for Cases of Canine Distemper and Characterization of Clinical Signs in Presenting Patients. Asian journal of microbiology and biotechnology. 2025. DOI: https://doi.org/10.56557/ajmab/2025/v10i19171

[55] Brown AT, McAloose D, Calle P, Auer A, Posautz A, Slavinski S, et al.. Development and validation of a portable, point-of-care canine distemper virus qPCR test. PLoS ONE. 2020. DOI: https://doi.org/10.1371/journal.pone.0232044

[56] Brown AT, McAloose D, Calle P, Auer A, Posautz A, Slavinski S, et al.. Individual sample results and metadata from CDV suspect, Austrian mesocarnivores.. . 2020. DOI: https://doi.org/10.1371/journal.pone.0232044.s001

[57] Stancu A, Voia O, Boldura O, Pașca S, Luca I, Hulea A, et al.. Unusual Canine Distemper Virus Infection in Captive Raccoons (Procyon lotor). Viruses. 2023. DOI: https://doi.org/10.3390/v15071536

[58] Iribarnegaray V, Godiño G, Larrañaga C, Yamasaki K, Verdes J, Puentes R. Droplet Digital PCR Enhances Sensitivity of Canine Distemper Virus Detection. Viruses. 2024. DOI: https://doi.org/10.3390/v16111720

[59] Shi Y, Long F, Shi K, He M, Shi Y, Feng S, et al.. A Quadruplex Reverse Transcription Quantitative Polymerase Chain Reaction for Detecting Canine Coronavirus, Canine Rotavirus, Canine Parvovirus, and Canine Distemper Virus. Microbiology Research. 2024. DOI: https://doi.org/10.3390/microbiolres15020049

[60] Echeverry-Bonilla D, Buriticá-Gaviria E, Orjuela-Acosta D, Chinchilla-Cárdenas D, Ruíz-Sáenz J. The First Report and Phylogenetic Analysis of Canine Distemper Virus in Cerdocyon thous from Colombia. Viruses. 2022. DOI: https://doi.org/10.3390/v14091947

[61] Harkin K, Karote AG. Evaluation of Intrathecal Injection of Modified Live Newcastle Disease Virus Vaccine in Dogs with Canine Distemper Encephalitis.. The Journal of the American Animal Hospital Association. 2022. DOI: https://doi.org/10.5326/JAAHA-MS-7077

[62] Van PD, Mai NTA, Nguyen VT, Nguyen TTH, Dong HV, Le PN, et al.. Detection and genetic characterization of canine distemper virus isolated in civets in Vietnam.. Research in Veterinary Science. 2022. DOI: https://doi.org/10.1016/j.rvsc.2022.12.004

[63] Shi P, Wang Z, Sheng W, Wang Z, Wang S, Zhang C, et al.. Whole-canine neutralizing antibodies generated by single B cell antibody technology elicit therapeutic protection against canine distemper virus infection.. Veterinary Microbiology. 2025. DOI: https://doi.org/10.1016/j.vetmic.2025.110412

[64] Zhao J, Sun Y, Sui P, Pan H, Shi Y, Chen J, et al.. DNA Vaccine Co-Expressing Hemagglutinin and IFN-γ Provides Partial Protection to Ferrets against Lethal Challenge with Canine Distemper Virus. Viruses. 2023. DOI: https://doi.org/10.3390/v15091873